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ABSTRACT 
Background. Multiple sclerosis (MS) has been traditionally described as an autoimmune 
disease of adaptive immunity affecting the white matter (WM) of central nervous system. 
Recent scientific interest has focused on the role of the innate immunity and structures 
including the normal-appearing WM (NAWM), grey matter (GM) and black holes (BH). PET 
imaging using [
11
C]-PK11195 (PK), allows the in vivo visualization of activated microglia. 
Aims. This project aims to study in vivo the role of microglia activation in three specific 
structures, BH, GM and NAWM and, in a wide range of patients, from clinically isolated 
syndromes (CIS) to the later stages of progressive course. This study also aims to identify 
prognostic factors which could be useful as indicators for early treatment and in later stages 
for disability progression. 
Methods. Subjects: twenty MS, 18 CIS and 8 healthy controls (HC). Procedures: clinical 
history, neurological examination, PK-PET and MRI scans. MS subjects have been followed 
up only clinically, while CIS also with repeated MRI, yearly, for 2 years. The PK binding 
potential is referred to the non-displaceable radioligand (PKBPND). 
Results. In progressive patients BH PKBPND correlated with disability and represented a 
significant predictor of disability. In NAWM the PKBPND was increased in patients compared 
with HC and within the MS subgroups it increased with the stage. In CIS subjects PKBPND 
was predictive of MS diagnosis at 2 years and in progressive patients of worse clinical 
outcome. GM central structures (CS) showed increased PKBPND in CIS vs HC. A prognostic 
value for the cortex is reported in progressive patients. 
Discussion: PK-PET imaging has shown new insights into BH, NAWM and GM structures 
that are relevant for the understanding of MS pathology. This includes the relevance of 
activated microglia in BH, in CIS NAWM and CS, in MS cortical GM as a predictor for 
clinical progression. 
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CHAPTER 1: Introduction 
Definition 
Multiple sclerosis (MS) is one of the commonest causes of disability in young adults 
(Sadovnick and Ebers, 1993). It is characterized pathologically by areas of inflammatory 
demyelination and axonal loss that affect the central nervous system (CNS) (Evangelou et al., 
2000; Noseworthy et al., 2000). 
Multiple sclerosis phenotypes 
The latest definition of MS phenotypes (Lublin et al., 2014) by the Committee composed by 
the US National MS Society, the European Committee for Treatment and Research in MS 
and the MS Phenotype Group, identifies the following MS courses: 
1. Clinically isolated syndrome (CIS) represents the first clinical presentation of a 
disease that shows characteristics of inflammatory demyelination that could be MS; 
2. The relapsing-remitting (RR) course was defined in the previous Committee 
convention (Lublin and Reingold, 1996) as clearly defined disease relapses with full 
recovery or with sequelae and residual deficit upon recovery in the lack of disease 
progression and a relapse as acute worsening of neurologic function followed by a 
variable degree of recovery, with a stable course between attacks; 
3. The secondary progressive (SP) MS is characterised by a history of gradual 
worsening after an initial relapsing disease course, with or without acute 
exacerbations during the progressive course; 
4. The primary progressive MS course is defined by the Committee of 1996 as disease 
progression from the onset, with occasional plateaus and temporary minor 
improvements allowed. 
Clinical epidemiology 
More than 80% of subjects who subsequently develop MS initially have a CIS (Richards et 
al., 2002), a single clinical episode suggestive of MS. Abnormalities on magnetic resonance 
imaging (MRI) (Jacobs et al., 1986; Miller et al., 1987; Ormerod et al., 1986), the presence of 
oligoclonal bands (OB) (Lee et al., 1991; Paty et al., 1988) and the anatomical site of the 
inflammation (Beck et al., 2003; Brex et al., 2002; Miller et al., 1989; Minneboo et al., 2004; 
Tintoré et al., 2005), are predictors of the MS development. In patients with CIS the best 
current investigation predictive of the future development to MS is the number of white 
matter (WM) lesions (plaques) present on MRI (Chard et al., 2011; Fisniku et al., 2008). 
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During the early phases of MS, about 80-85% of subjects presents with a relapsing course, 
characterized by the sudden onset of symptoms referable to focal CNS lesions, with complete 
or partial recovery; the remaining 15-20% of patients has a progressive course since the 
onset, characterized by slow accumulation of non-recoverable disability (Richards et al., 
2002). The progressive course appears more often in the later stages of disease, in about 32-
65% of patients with the relapsing onset (Confavreux et al., 2000; Cottrell et al., 1999; 
Kremenchutzky et al., 1999). Epidemiological studies showed that the number of relapses 
does not significantly influence the accumulation of irreversible disability (Cottrell et al., 
1999; Kremenchutzky et al., 1999, 2006; Scalfari et al., 2010). After the onset of progression 
the disease follows a uniform course, no matter whether primary or secondary (Confavreux 
and Vukusic, 2006; Kremenchutzky et al., 2006).  
Risk factors 
Multiple sclerosis affects 2,5 million of people worldwide (Alastair Compston, 2005), with a 
highly uneven geographical distribution (Ebers, 2008). Both genetic and environmental 
factors have been shown to be relevant in the pathogenesis of MS, although none of these is 
necessary or sufficient to cause the disease. 
An interesting example of how genetic and environmental factors can interact is the change in 
female to male ratio. It was reported in Canada and Scotland to be around 1 respectively in 
1900s (Orton et al., 2006) and 1950s (Sutherland, 1956), it now exceeds 3 in both the 
countries. This effect is present also in the population emigrated from Europe to Canada 
during the same period (Orton et al., 2006). These reports might suggest that a change in the 
exposure to environmental factors of the same populations (with genetic as a constant) 
interacted in different ways in the two genetic subpopulations (F/M). 
Genetic 
The strongest evidence supporting a role for the pathogenesis of MS is given by the studies of 
families, in particular those with twins. Considering a decreasing genetic concordance in 
mono-, dizygotic twins (and siblings), half siblings, the percentage of MS diagnosis 
decreased in parallel, being respectively of 20.1%, 3.1% and 1.9% (Ebers et al., 2004; Willer 
et al., 2003). Interestingly, the concordance of female dizygotic twins was higher than for 
male dizygotic twins, respectively 34% vs 6.5% (Willer et al., 2003) and the maternal half 
siblings had higher concordance than the paternal ones, respectively 1.8% and 0.9% (Ebers et 
al., 2004). The incidence of MS diagnosis of patients offspring was also reported increased to 
5.9% (Robertson et al., 1997). 
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The well known association of the disease with variants of human leukocyte antigen (HLA) 
was first reported longer than 40 years ago (Jersild et al., 1972). This was recently enhanced 
in one of the periodic reports of the International Multiple Sclerosis Genetics Consortium 
(IMSGC) and the Welcome Trust case control consortium 2 (International Multiple Sclerosis 
Genetics Consortium et al., 2011) which was particularly focused on the cell-mediated 
immune mechanism. With regards to the HLA, they confirmed the previously reported strong 
association of MS with DRB1*15.01 (Sawcer et al., 2005) and reported a protective role for 
the HLA-A*02:01. The presence of the HLA allele DRB1*13:03, alone or associated with 
DQB1*02:01, showed an additional risk for MS. The allele DRB1*15.01 was also confirmed 
to be associated with the age at onset, previously reported by Masterman and coll. 
(Masterman et al., 2000) . Further to the HLA, they found 95 regions and 102 single 
nucleotide polymorphisms (SNPs) associated with MS, including cytokine pathways, co-
stimulatory and signal transduction molecules, environmental factors, molecules related to 
monoclonal antibody treatments and neurodegeneration pathways independent of 
inflammation. A strong evidence for the contribution of the immune system dysregulation 
attributed to the presence of numerous genes involved in the T cell differentiation was also 
reported. 
To further indicate the importance of genetic factors in the pathogenesis of MS, the last report 
of the IMSGC (Beecham et al., 2013) found 97 statistically independent SNPs, including 93 
primary and 4 secondary signals (48 new). This report stressed the immunological role of the 
signalling molecules found to be relevant. As a matter of interest, they reported that about 
22% of these signals significant for MS, overlapped with at least one of the other 
autoimmune disease signals. 
One example of genetic influence on MS is the high prevalence in Sardinia, 144/100000 
(Pugliatti et al., 2001), compared with the low one in Corsica 53/100000 (Vukusic et al., 
2007), that could not easily be explained by environmental factors, while a genetically driven 
risk is highly supported by the great genetic distance between Sardinians and the rest of 
Europe (Cavalli-Sforza, 1994). 
Environmental 
Studies on geographical distribution of MS prevalence in population with the same genetics 
can be very helpful in identifying the environmental risk factors. One example is the 
distribution of French farmers. Vukusic and coll. reported a north-south gradient and an east 
to west one (Vukusic et al., 2007). This was consistent with a range of prevalence paralleling 
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the amount of sunlight during winter. In this case the lower sunlight exposure seems to be a 
strong risk factor, further supported by the general north-south gradient present in Europe and 
North America. Nevertheless, in Norway this geographical gradient of prevalence goes in the 
opposite direction (Kampman et al., 2007). One explanation might reside in the diet, in 
particular oily fish, which points to another important environmental risk factor for MS, the 
intake of Vitamin D. A further example is supported by the migration studies, such as the one 
from India to United Kingdom. People from India (low prevalence) acquired a MS risk 
similar to the population in UK (high prevalence) from the second generation (Elian et al., 
1990). In this case, there seem to be two variables to consider. One is the presence of an 
environmental risk factor in UK higher than in India; the other is the timing: in order to be 
effective for the onset of MS, subjects need to be exposed to the risk factor during their 
young age. 
The most important non-infectious environmental risk factors are therefore the exposure to 
sunlight (Acheson et al., 1960; Antonovsky et al., 1965; Cendrowski et al., 1969; Freedman 
et al., 2000; Goldacre et al., 2004; Kurtzke, 1967; Leibowitz et al., 1967; van der Mei et al., 
2001, 2003; Sutherland et al., 1962) and the intake of vitamin D (Brustad et al., 2004; 
Feskanich et al., 2003; Munger et al., 2004; Salvini et al., 1989; Swank et al., 1952; 
Westlund, 1970; Willett, 1998; Willett et al., 1988). Further to those, smoking was both 
shown to increase the risk of MS onset (Hernan et al., 2001; Thorogood and Hannaford, 
1998; Villard-Mackintosh and Vessey, 1993) and the switch of the disease to a progressive 
course (Hernan et al., 2005). 
Finally, regarding the infectious risk factors for MS, the most important and the last remained 
to be excluded (or confirmed) is the association with Epstein-Barr virus (EBV) infection. 
Briefly, the evidences supporting a role for EBV infection on the pathogenesis of MS 
involve: (i) the seroprevalence, a lower risk is reported in seronegative subjects, with a 0.06 
total odds ratio (Ascherio et al., 2001; Bray et al., 1983; Ferrante et al., 1987; Haahr et al., 
2004; Larsen et al., 1985; Munch et al., 1997; Myhr et al., 1998; Ponsonby et al., 2005; 
Shirodaria et al., 1987; Sumaya et al., 1980, 1985; Sundstrom et al., 2004; Wagner et al., 
2000); (ii) the history of infectious mononucleosis (and its timing), which significantly 
increases the risk of developing MS (Cohen, 2000; Thacker et al., 2006) of an up to 20-folds 
magnitude; (iii) higher titres of anti-EBV in MS subjects (Larsen et al., 1985; Shirodaria et 
al., 1987), especially anti-EBNA1 (Ascherio et al., 2001; DeLorenze et al., 2006; Levin et al., 
2005; Sundstrom et al., 2004), and the importance of the age at seroconversion (Levin et al., 
2005); (iv) EBNA-1 specific circulating CD4, with higher frequency and broader specificity 
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in patients with MS than controls (Lunemann et al., 2006), also reported for the CD8 
subpopulation of CIS subjects (Jilek et al., 2008). 
Neuropathology of MS 
In MS the whole CNS is affected by pathological changes. Despite a subdivision in 
pathological regions of interest (ROIs) does not completely represent a wider picture 
constantly changing, especially in different stages of the disease, typically it is possible to 
describe WM lesions, pathological changes in the normal appearing WM (NAWM) and 
cortical lesions. 
The WM lesions are pathologically classified according to their stage (preactive, early active, 
late active, chronic active, chronic inactive and shadow plaques) on the basis of the degree of 
inflammation and demyelination (Frohman et al., 2006; Lassmann et al., 1998; Reynolds et 
al., 2011). Classically the pathological process starts with microglial aggregates, then 
lymphocytes and macrophages perivascular infiltrates, followed by increasing demyelination 
with macrophages positive for myelin inclusions (Barnett and Prineas, 2004). While in early 
active lesions the margins are indistinct, in chronic plaques the edges are sharp, with 
inflammatory cells present at the periphery (active) or mostly absent (inactive). Shadow 
plaques are characterised by a reduced density in myelin staining due to an inferior number 
and thickness of the sheaths, often seen in remyelinating plaques. Different patterns of WM 
lesion have been described, even if there is no unanimous consensus on it. Four  patterns of 
actively demyelinating lesions have been described (Lucchinetti et al., 2000; Metz et al., 
2014), respectively characterised by (i) sharp edges lesions with macrophage and T 
lymphocytes infiltrates centred on small veins, in which all the myelin proteins are involved; 
(ii) similar to pattern I plus deposition of Ig and complement at site of demyelination; (iii) ill-
defined margins spreading into the surrounding WM, T cell and macrophage infiltration not 
centred on vessels, the myelin protein mostly involved was the myelin-associated 
glycoprotein with great loss of oligodendrcytes in apoptosis at the edge of the lesion; (iv) 
sharped edge lesions with a radial and non-apoptotic loss of oligodendrocytes (also present in 
the periplaque WM) without myelin protein preference, infiltrates of macrophage and T 
lymphocytes. This pattern subdivision was described, across the patients, as heterogeneous 
between subjects but homogenous within active lesions of the same patient. However, other 
studies (Breij et al., 2008) reported one single pattern as common pattern in established MS, 
characterised by areas of active demyelination and macrophages infiltrates with deposition of 
Ig and complement. 
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Out of the macroscopically visible lesions, the NAWM was not shown to be through and 
through normal. Howell showed a predominant activation of microglia associated with 
disruption of the axo-glial unit and axonal loss, independent of demyelinating lesions and 
lymphocytes infiltration (Howell et al., 2010). Functionally, microglia in NAWM was 
investigated in a post mortem study in which microglia (isolated ex vivo) was examined in 
vitro (Melief et al., 2013). Microglia from NAWM was shown to be increased in size with 
high granularity, expressing high levels of CD45 (activation marker) and having almost 
absent CD206 (expressed in alternatively activated microglia) at fluorescence-activated cell 
sorting; using quantitative polymerase chain reaction, microglia displayed an upregulation of 
CD32b (low affinity immunoglobulin gamma Fc region receptor II-b) and their culture was 
lacking of response to lipopolysaccharide (LPS), while stimulation with dexamethasone 
suppressed the expression of CD18 (neurotoxic microglia). Reporting these results, authors 
defined microglia like immunoregulated in NAWM, as alerted, even with characteristics of 
immunosuppression, reflecting a response to ongoing neuroinflammation. Two studies were 
performed using microarrays to explore the NAWM in MS patients. The first  showed 
upregulation of genes usually involved in the maintenance of homeostasis after hypoxic 
injuries, including neuroprotection against oxidative stress (Graumann et al., 2003a). The 
second  found the expression of genes involved in the cellular immunity being equally 
upregulated in lesions and NAWM, while in lesions there was only a higher expression of 
genes for Ig synthesis and neuroglial differentiation (Lindberg et al., 2004). An interesting 
study correlated the neuropathological changes and MRI imaging on MRI-defined NAWM 
(Moll et al., 2011). The comparison was performed on four types of ROIs from SPMS 
donors: (i) T2 lesions, (ii) abnormal magnetization transfer ratio (MTR) close to lesions, (iii) 
abnormal MTR far from lesions and (iv) NAWM, both normal on T2 and MTR. They found 
the abnormal MTR signal being associated with axonal swelling only in NAWM close to 
lesions; NAWM with abnormal MTR signal was associated with microglial activation which 
correlated to the reduced MTR; NAWM defined at T2 MRI sequences, when associated with 
reduced MTR were usually close to cortical lesions. 
Grey matter (GM) lesions are characterised by demyelination and neuronal loss, with minor 
presence of inflammatory cells (Bö et al., 2007; Gilmore et al., 2009; Magliozzi et al., 2010; 
Peterson et al., 2001), however present in the newly forming lesions (Pirko et al., 2007) and 
in leptomeninges (Frischer et al., 2009; Guseo and Jellinger, 1975; Kutzelnigg et al., 2005; 
Magliozzi et al., 2007). The higher importance attributed recently to GM pathology in MS is 
also suggested by the number of studies reporting neocortical involvement (Bo et al., 2003; 
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Kutzelnigg et al., 2005; Peterson et al., 2001) as well hippocampal (Geurts et al., 2007) and 
cerebellar (Kutzelnigg et al., 2007). GM lesions have been characterised in patterns (Peterson 
et al., 2001) according to their anatomical position in the GM: (i) lesions contiguous with 
subcortical WM lesions; (ii) small lesion within the cortex, often perivascular; (iii) subpial 
lesions, up to cortical layer 3 or 4. A recent post mortem study explored the specificity of MS 
active lesions in the GM, comparing them to pathological changes present in other 
neurodegenerative diseases with a wide range of inflammation (tuberculous, luetic, chronic 
purulent meningitis, B cell lymphoma, Rasmussen encephalitis, Alzheimer disease), further 
to controls (Fischer et al., 2013). Using microarrays on active GM lesions, they found MS 
specific features involving the inflammation pathways and mechanisms of oxidative injury, 
which were higher than in other inflammatory conditions and mainly affecting 
olygodendrocytes and neurons; finally they reported MS specific regenerative mechanisms. 
This study stresses the importance of inflammation as predominant cause of 
neurodegeneration in MS. 
Regarding the inflammatory infiltrates, it is worth mentioning that there is a wide consensus 
about the switch from a high component from periphery during the initial phases of the 
disease, towards a compartmentalisation of the inflammation occurring during the later 
stages, in particular the progressive phase (Hochmeister et al., 2006; Kutzelnigg et al., 2005; 
Lassmann et al., 2007; Magliozzi et al., 2010; Reynolds et al., 2011; Stadelmann, 2011; 
Thompson et al., 1991). This compartmentalisation of inflammation, feature of progressive 
MS, is strongly associated with neurodegeneration (Kutzelnigg et al., 2005), being activated 
microglia reported as its major mediator (Howell et al., 2010, 2011). This concept is further 
supported by the description of lymphoid-like structures in the meninges of SPMS patients 
(Magliozzi et al., 2007; Serafini et al., 2004) associated with increased microglial activation, 
subpial cortical demyelination and neurodegeneration and worst prognosis. The hypothesis 
that in a condition of compartmentalised inflammation the presence of lymphoid-like 
structures might sustain through the secretion of soluble factors the progressive cortical 
demyelination and neurodegeneration was also formulated (Magliozzi et al., 2007, 2010). 
Immunology of MS 
The immune system contribution to the MS pathogenesis is essential. Evidences support a 
different role for the innate and adaptive immunity. The innate immune system represents the 
first line of defence, acting both as a sensor and as first reactor against threats to the CNS. 
Further roles of the innate immune system in the MS pathogenesis include mutual regulation 
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with the adaptive immune system and the homeostatic and wound-healing properties. 
Adaptive immunity in MS is involved in the antigen specificity, through several B and T cell 
clones expanding to target more selectively and efficiently the CNS structures. 
Innate 
The cell populations of the CNS innate immune system include the microglial and 
macrophage, dendritic, astrocyte, mast, natural killer (NK), invariant NK T and γδ-T cells. 
For all of these cell populations several lines of evidence describe their contribution to MS 
pathogenesis.  
Dendritic cells 
Further to microglia and macrophage, to which a separate paragraph is dedicated, the 
dendritic cells (DC) mainly represent the professional APC (Maldonado-Lopez et al., 1999, 
McMahon et al., 2005). They derive from bone marrow (Bailey et al., 2007; Deshpande et al., 
2007) and infiltrate the CNS during inflammation (Bailey et al., 2007; Deshpande et al., 
2007). DC, in particular the myeloid (or conventional) subpopulation, were shown to be 
present in perivascular clusters with CD4 T cells (Bailey et al., 2007, Deshpande et al., 2007). 
They can activate naïve T cells involved in epitope spreading, which was reported to be 
initiated in the CNS and driven by DC acting as local APC (McMahon et al., 2005). DC from 
peripheral blood were shown to differently activate T cells in MS subjects according to the 
disease stage. DC from relapsing patients were able to induce both Th1 and Th2 phenotypes 
when co-cultured with naïve T cells taken from the cord blood, while DC from progressive 
patients induced only a Th1 phenotype (Karni et al., 2006). Myeloid DC were also reported to 
prime very efficiently a Th17 response (Mathers et al., 2009; Shainheit et al., 2008). 
Furthermore a specific subset of DC, the IL-10-producing DC (DC-10), was shown to be 
tolerogenic and induce the type 1 T regulatory cells (Bailey et al., 2007; Deshpande et al., 
2007). 
Astrocytes 
The main role of astrocytes is related to their high number and strategic position aiming to 
maintain the homeostasis of the CNS, protecting it from any kind of threat. They are the first 
CNS cell population of the blood-brain barrier (BBB), maintaining and regulating the 
isolation of the CNS (Nair et al., 2008). Further to the non-immunological roles, such as the 
production of trophic factors or stabilization of the extracellular concentration of potassium 
or metabolism of glutamate (Kimelberg, 2010), they were reported to actively contribute to 
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the pathogenesis of MS, especially in studies based on animal models of MS, both 
experimental autoimmune encephalomyelitis (EAE) (Carpentier et al., 2005; Constantinescu 
et al., 2005; Korteweg et al., 2006; Oren et al., 2004; Soos et al., 1999; Tan et al., 1998) and 
Theiler's murine encephalitis virus-induced demyelinating disease (TMEV-IDD) (Barcia et 
al., 2006, 2008a, 2008b; Carpentier et al., 2008; Zheng et al., 2001). Even if they are not 
professional APC, under IFNγ stimuli they can express MHC-II (Tan et al., 1998; Vass and 
Lassmann, 1990), further to induced/upregulated co-stimulatory molecules for T cell 
interaction, such as CD80 and CD86 (Nikcevich et al., 1997, Cornet et al., 2000). Regarding 
the effect on T cells, evidences show their ability to activate naïve T cell to different 
phenotypes, such as Th1, producing IL-12, Th2, producing IL-4, and Th17, producing IL-23 
(Constantinescu et al., 2005). Finally, in presence of IL-17, they produce CCL2, CCL12, 
CXCL1 and CXCL2 (Kang et al., 2010; Sarma et al., 2009), promoting autoimmune 
pathology in the CNS (Onishi and Gaffen, 2010). Considering their properties, in the overall 
viewpoint of MS pathogenesis, they can therefore be either protective or armful. 
Mast cells 
As part of the innate immune system, mast cells (MC) have a role as sensor and first reaction 
against several kinds of threat. They have a perivascular location (Minagar and Alexander, 
2003; Silver et al., 1996) in the CNS and their activation includes the release of vasoactive 
and BBB permeabilising mediators (Minagar and Alexander, 2003). MC are also present in 
MS plaques (Bebo et al., 1996; Ibrahim et al., 1996), where they contribute to the tissue 
damage by increasing their cytotoxic degranulation, and in cerebrospinal fluid (CSF), where 
tryptase of MC origin was found (Rozniecki et al., 1995). In EAE activated MC were also 
found in meninges, releasing TNFα, which increases the recruitment of immune cells from 
peripheral blood (Sayed et al., 2010). Finally, MC-deficient mice are reported to have a 
clinically milder onset and disease development both for the myelin oligodendrocyte 
glycoprotein (MOG)-induced model of EAE (Secor et al., 2000) and the SJL mice 
immunized with proteolipid protein (Sayed et al., 2011). 
NK T cells 
The physiologic role of NK cells is to sustain a cytotoxic reaction against infected and 
neoplastic cells. In MS, as well as most of the innate immune cell population, they can have a 
protective or detrimental effect. Evidences regarding the first include a more severe EAE in 
NK-depleted mice, with an increased Th1 response profile (Segal, 2007). Furthermore, the 
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impaired recruitment of NK cells explored by the use of CX3CR1 deficient mice, reduced the 
inhibition of Th17 cells by NK, exacerbating the disease (Hao et al., 2010). On the opposite, 
NK cells were also shown to have a detrimental role. Their functional activity correlated with 
the risk of disease activity, both clinical and at MRI imaging (especially for new active 
lesion), in RRMS subjects (Kastrukoff et al., 1998). NK cells can be also activated by 
astrocyte-secreted IL-12 (Pagenstecher et al., 2000), increasing the release of a number of 
cytokines including IFNγ and promoting the Th1 skew (Shi et al., 2000). Both of the opposite 
roles have also the additional proof of NK-depleting antibody, shown either to ameliorate 
(Winkler-Pickett et al., 2008) or exacerbate (Zhang et al., 1997) the disease. This double role 
of NK cells in MS is probably due to their interaction with DC, by which in some conditions 
they can be activated, increasing their cytotoxicity, and in others they can either promote DC 
maturation (Ferlazzo et al., 2002; Gerosa et al., 2002; Piccioli et al., 2002; Zitvogel, 2002) or 
death (Carbone et al., 1999; Spaggiari et al., 2001; Wilson et al., 1999). Interestingly, during 
treatment with Daclizumab (anti-CD25), shown to be effective in MS (Gold et al., 2013), 
there is a drastic increase of circulating NK T cells (Bielekova et al., 2011) . 
Invariant NK (iNK) T cells are a distinct subpopulation of NK-T cells characterised by the 
expression of an invariant α chain for the T cell receptor (TCR) (Vα24-Ja18). They have 
typically inhibitory effects in autoimmune diseases (Van Kaer, 2005) and their activation, in 
laboratory through α-galactosyl ceramide, is associated with a clinically milder EAE (Parekh 
et al., 2004; Singh et al., 2001). The mechanism is not completely clear yet, but three 
different studies reported iNK T cells to exert their inhibitory effect either on DC, 
monocytes/macrophages or myeloid-derived suppressor cells (MDSCs). The first reported a 
switch of DC towards a more regulatory phenotype, more immature and secreting higher 
levels IL-10 and lower of IL-12 (Kojo et al., 2005). The second showed the suppressive effect 
to be associated with monocytes acquiring a M2 macrophage phenotype (Denney et al., 
2012). The third reported iNK T cells to promote the activation of MDSCs and enhancing 
their ability to suppress pathogenic T cells (Parekh et al., 2013). 
γδ-T cells 
γδ-T cells are lymphocytes with TCR composed by invariant gamma and delta chains. 
Likewise other cell population pertaining to the innate immunity, their role in the MS 
pathogenesis is controversial and probably not univocal. They are present in MS plaques 
(Selmaj et al., 1991) and, upon astrocytes activation (Freedman et al., 1997), have a cytotoxic 
effect on oligodendrocytes (Freedman et al., 1991). They were found increased in the CSF of 
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MS subjects (Mix et al., 1990; Shimonkevitz et al., 1993), parallel to the increase in 
peripheral blood (Stinissen et al., 1995), especially in subjects displaying active disease 
(Rinaldi et al., 2006), including in progressive patients (Chen and Freedman, 2008). In EAE 
they were reported to be either detrimental (Odyniec et al., 2004) and protective (Kobayashi 
et al., 1997). Probably, also for γδ-T cells different subsets exert opposite effects on the MS 
pathogenesis, like was recently described, one promoting a Th17 environment, the other 
producing a more regulatory response (Blink et al., 2014). 
Adaptive 
Although a specific antigen inducing MS has not been found, several evidences support the 
involvement of the adaptive immune system in the MS pathogenesis, for both B and T cells, 
starting from the induction of EAE in rats by intravenous (IV) injection of encephalitogenic T 
cells (Bartholomäus et al., 2009; Ben-Nun et al., 1981). Within the evidences can be 
included: (a) the finding of OB in affected subjects, sign of intrathecal synthesis of Ig mainly 
pertaining to the G isotype, with a prevalence of 69% (Lee et al., 1991) in CIS, which 
increases during the disease course and a recent meta-analysis estimated to have a predictive 
sensitivity of 73-100% (Skov et al., 2011); (b) the finding of antibodies in the CSF of MS 
patients targeting αβ-crystallin (Ousman et al., 2007), neurofascin (Mathey et al., 2007) and 
neuronal proteins (Bartos et al., 2007; Silber et al., 2002); (c) the strong CD8 activation 
against EBV in CIS patients (Jilek et al., 2008) and B cells reactivation in MS, which can also 
suggest a role for their reciprocal balance with CD4 memory T cells and Tregs within the 
abnormal regulation of EBV infection in MS patients (Lunemann et al., 2006; Serafini et al., 
2007); (d) the presence of Ig-producing B cells and plasma cells in chronic MS lesions 
(Ozawa et al., 1994; Prineas and Wright, 1978) and the B cell clonal expansion as a 
prominent feature of the IgG repertoire in MS patients (Owens et al., 2003); (e) the presence 
of restricted patterns of rearranged Ig mRNA within the plaque lesion (Baranzini et al., 
1999); (f) the description of intrameningeal lymphoid-like structures with proliferating B 
cells, suggestive of germinal centre formation in SPMS brains, associated with severe cortical 
demyelination, increased number of active cortical lesions and a more pronounced microglia 
activation and neurite loss (Magliozzi et al., 2007; Serafini et al., 2004); (g) the effectiveness 
of the anti-CD20 Ab Rituximab (Bar-Or et al., 2008; Hauser et al., 2008; Naismith et al., 
2010) and anti-VLA4 Ab Natalizumab in relapsing patients (Polman et al., 2006; Rudick et 
al., 2006), together with other less specific immunomodulators (Cohen et al., 2010a; 
Giovannoni et al., 2010; Jacobs et al., 1996; Johnson et al., 1995; Kappos et al., 2010; 
29 
 
PRISMS Study Group, 1998; The IFNB MS Study Group, 1995); (h) the myelin basic protein 
(MBP) 83-99 trial showed the importance of the T cells in the pathogenesis of MS, despite 
(or confirmed by) the failure of the trial (Bielekova et al., 2000; Kappos et al., 2000); (i) the 
role of pathogenic Th17 cells population and its complex and still debated peripheral 
regulation (Esplugues et al., 2011; Langrish et al., 2005; Miyazaki et al., 2011). 
Microglia 
In 1878 Carl Frommann described, in CNS tissue of a deceased 22-year old MS patient, glial 
cells morphology changes in brain and spinal cord. The morphology changes consisted in 
larger soma, shorter and less numerous processes; there was a higher density of these cells 
with granulated soma containing inclusions, which seemed to occupy the epicentres of 
histological damage (Kettenmann et al., 2011). In 1932 Pio del Rio Hortega reported a series 
of characteristic of these called microglia cells: they enter the brain during the early 
development, have amoeboid morphology and mesodermal origin, use vessels and WM tracts 
as guiding structures for migration and settle in all the brain regions; in mature brain, they 
display little variation and transform into a branched, ramified morphological phenotype, 
evenly dispersed throughout the CNS, apparently occupying a defined territory; they undergo 
a transformation after a pathological event, acquiring an amoeboid morphology similar to the 
one observed early in development, having the capacity to migrate, proliferate and 
phagocytose (Kettenmann et al., 2011). 
Nowadays, the mesodermal/mesenchymal origin has been demonstrated (Chan et al., 2007), 
the brain invasion occurs in two waves, during the first 2 trimesters (foetal development) and 
the early postnatal days. Regarding the renewal there is now a general consensus that in 
normal brain microglia is a stable population, may persist for decades and aging can be 
relevant for altered capacity (even harmful) (Sierra et al., 2007; Streit, 2006); only in 
pathological conditions, especially those with an inflammatory BBB breakdown, a large 
number of monocytes can invade the brain (Djukic et al., 2006; Flügel et al., 2001; Ladeby et 
al., 2005; Lawson et al., 1992). Furthermore, a perivascular population of cells that shares 
features with immature microglia with a 14 weeks turnover was described (Bechmann et al., 
2001a, 2001b). 
Microglia represent the resident macrophage population of the CNS. Their function is to 
sense any possible CNS threat and re-establish the tissue homeostasis. There is hence a 
sensing/resting microglia and a restoring/active phenotype. The first has a ramified 
morphology, with small soma and fine and long cellular processes. The second displays an 
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amoeboid morphology characterised by a reduction of the cellular processes and increased 
motility. This latter phenotype is able to actively migrate to a lesion following chemotactic 
gradients, increasing its density in the threatened tissue even proliferating. By the functional 
concerns, being microglia similar to macrophages, at least two activated phenotypes were 
described (Butovsky et al., 2005, 2006a). One can be induced by LPS, β-amyloid aggregates 
and promotes phagocytosis, the release of inflammatory mediators and doesnt facilitate cell 
renewal (Hanisch and Kettenmann, 2007). Another microglial phenotype is induced by 
cytokines such as IL-4 (or little amount of IFNγ) and promotes the apoptotic cells and myelin 
debris removal and the release of anti-inflammatory factors, supporting oligodendrogenesis, 
neurogenesis and neuroprotection (Butovsky et al., 2006b). 
In MS microglia is fundamental to the pathogenic process. In the early stages of the disease 
microglia, firstly as threat sensor then as APC, once activated, can recruit naive T cells from 
peripheral blood in the inflamed CNS, bypassing the need of activation in peripheral 
lymphoid sites. The activation of naive T cells involved in epitope spreading initiates in the 
CNS and is driven by local APC; DC are likely to have more relevance in the latter role 
(McMahon et al., 2005), although the microglial capacity of re-stimulation of the tissue-
invading memory T cells is essential in a disease like MS where the persistence of a specific 
immune activation supports the sustained long term pathological features. In the presence of 
IFNγ and TNFα, the expression of ICAM-1, CD40, B7.2, and B7.1 is dramatically up-
regulated, allowing microglia to interact with T cells in an antigen-specific manner (Aloisi, 
2001; Nguyen and Benveniste, 2002). The ways in which microglia contribute to the further 
disease development is the result of the interaction with other cell populations and their by-
product microenvironment. The balance in these extended feedbacks between cell 
populations in MS is mostly relevant regarding the microglia-T cells and microglia-neurons 
interactions, even if all the cell populations (both CNS resident and blood derived) have 
fundamental roles. Concerning the microglia-T cells interaction, several evidences supported 
the possibility that different T cell subpopulations (such as Th1-Th2) influence in opposite 
direction the expression of MHC class II and co-stimulatory molecules in microglia. In turn, 
by secretion of IL-12 microglia can modulate the T cells production of IFNγ, which can 
stimulate microglia in producing TNFα. The fact that T cells and microglia can reciprocally 
affect their phenotype is one of the major contributors in altering the complex balance in 
CNS microenvironment between the different types of cell populations. 
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Alteration of the CNS homeostasis 
It is a currently accepted opinion that inflammation represents the pathological correlate of 
the clinical phenomenon of the relapse, whereas neurodegeneration is the most relevant 
pathological aspect of progression (Bjartmar et al., 2000; Felts et al., 1997; Geurts and 
Barkhof, 2008; Lovas et al., 2000; Pelletier et al., 2003; Waxman, 1998). Nevertheless, the 
neuropathology of MS appears to be much more complex and the primary cause of the CNS 
homeostasis alteration is not known yet (Hauser and Oksenberg, 2006; Waxman, 2006). 
Whether the inside-out (Trapp and Nave, 2008) or the outside-in theory (Hohlfeld and 
Wekerle, 2004) is correct, or if the neurodegeneration in MS is primary or secondary to 
inflammation are hypothesis, not yet verified (Allan et al., 2005; Babcock et al., 2003; 
Centonze et al., 2007; Compston and Coles, 2008; Geurts and Barkhof, 2008; Linker et al., 
2005; Rocca et al., 2009; Trapp and Nave, 2008; Zipp and Aktas, 2006). However, the 
chronic alteration of homeostasis produces a microenvironment in which the pathway of 
neurodegeneration is often undertaken. 
The microglia-neurons interaction represents an example of how inflammation-induced CNS 
alterations can develop into neurodegeneration. In healthy subjects, microglia scan neurons 
and neural synapses throughout the CNS. Healthy neurons produce a microenvironment 
which strongly inhibits microglia. This is mainly mediated by CD200CD200R, CD22
CD45, CD172ACD47 (Barclay et al., 2002; Junker et al., 2009) and CX3CL1CX3CR1 
(Cardona and Ransohoff, 2009; Harrison et al., 1998). Consistent with the essential role of 
microglia in neurodegeneration is the report by Gao and coll. where 1-Methyl-4-
phenylpyridinium, LPS and rotenone, three toxins often used to create Parkinsons disease 
(PD) models, produced acute but non-progressive neurotoxicity in neuron-enriched cultures. 
In the presence of microglia, these toxins induced progressive neurodegeneration. More 
importantly, such neurodegeneration was prevented by removing activated microglia (Gao et 
al., 2011). Alterations of neurons and/or their microenvironment can therefore cause a weaker 
microglial inhibition resulting in their harmful activation, with the onset of a positive feed-
back which, if not modulated by other homeostatic factors, can lead to uncontrollable 
progressive neurodegeneration. 
In this context T cells could again have a key role. Under IL-10 and TGF- ! stimulation 
secreted by astrocytes and neurons, infiltrating T cells are induced to active apoptosis, 
through the death and signalling pathways. This is based upon members of the TNF super 
family and include CD95 (FasL)/CD95 (Fas) and the TNF-lymphotoxinreceptor-TNF 
receptor-1 (TNRF-1) (Choi and Benveniste, 2004; Felderhoff-Mueser et al., 2000; Flügel et 
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al., 2000; Lee et al., 2000; Saas et al., 1999). One important homeostatic factor in the 
interaction microglia-neurons, described by Magnus and coll., is performed with the aim of 
lymphocytes (Magnus et al., 2001). In this study, microglia phagocytosing apoptotic MBP-
specific T cells were compared with microglia phagocytosing non-apoptotic MBP-specific T 
cells. The former, significantly reduced the proinflammatory cytokines and modulated the T 
cells creating a more tolerogenic microenvironment. Encephalitogenic T cells resulted thus 
less activated through a reduced secretion of IL-12 and TNFα. The opposite effect resulted by 
co-culturing non-phagocytosing microglia with encephalitogenic T cells. In this study the 
microenvironment with microglial phagocytosis of apoptotic T cell showed a decreased 
secretion of the proinflammatory cytokines, TNFα and IL-12, while the secretion of IL-10 
and TGF-β was not affected.  Moreover, microglia increased MHC class II expression 
without concomitant increase in MHC class I, co-stimulatory molecules and ICAM 
expression. Several studies showed human lymphocytes stimulated in vivo by antigens to 
produce brain-derived neurotrophic factor  (BDNF) and nerve grow factor (Heese et al., 
1998; Kerschensteiner et al., 1999). In human MS lesions, BDNF positive cells 
morphologically resembling lymphocytes were described (Stadelmann et al., 2002). This 
finding supports the hypothesis that local antigen presentation can promote growth factors 
production at the site of damage (Carson, 2002). However other studies reported an impaired 
secretion of BDNF in RRMS lesions (Azoulay et al., 2008; Urshansky et al., 2010). 
One of the common neurodegenerative pathway enhanced by activated leukocytes and 
microglia is represented by the secretion of glutamate in CNS inflammatory conditions (Piani 
et al., 1991; Werner et al., 2001). The alteration of glutamate homeostasis (Forder and 
Tymianski, 2009) and its receptors, such as NMDA and AMPA, in MS were shown to be 
altered in opposite way with GABA. One example is the cortical GM hyperexcitability during 
MS relapses, resulting from imbalance between GABA and glutamate transmission (Caramia 
et al., 2004). These alterations were found in MS mice models, responsible for synaptopathy 
and neuronal death (Centonze et al., 2009). Activated microglia were shown to be essential in 
modulating the microenvironment associated with altered cortical transmission in 
neurodegeneration (Pinteaux-Jones et al., 2008; Taylor et al., 2005). Thus, despite T cells and 
microglia secrete proinflammatory cytokines, such as TNFα, (Block and Hong, 2005; 
Kawanokuchi et al., 2006; Muzio et al., 2007; Schwartz et al., 2006), it is also proven that the 
same milieu can be protective with regards to the recovery from neuroinflammation (Arnett 
et al., 2001). BDNF produced by microglia, T cells and astrocytes, supports remyelination in 
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focal and active WM lesion (Hohlfeld et al., 2000; Kerschensteiner et al., 1999; Stadelmann 
et al., 2002), but contributes to neuronal damage in MS GM, by increasing the glutamate 
release and influencing the function of its receptors (Carvalho et al., 2008; Frerking et al., 
1998; Li et al., 1998; Numakawa et al., 2001; Waterhouse and Xu, 2009). It appears therefore 
that the same mechanism aiming to protect the CNS during active inflammation represents at 
the same time one of the major causes of synaptopathy and neuronal death in the GM. Finally 
also the glutamate pathway has its feedback and can be modulated through the different 
expression of metabotropic receptors, with their pathways acting in opposite ways, mGlu2 
leading to neurotoxicity (Pinteaux-Jones et al., 2008; Taylor et al., 2005) and mGlu 3, 4 and 8 
supporting neuroprotection (Frischer et al., 2009), both expressed in MS lesions (Neumann, 
2001; Polazzi and Contestabile, 2006). 
Diagnosis 
The prerequisite for the MS diagnosis is the demonstration of spatial and temporal 
dissemination of typical lesions (Polman et al., 2011). The dissemination in space (DIS) and 
time (DIT) can be achieved through clinical, radiological (MRI), laboratory and 
neurophysiological assessment. 
Clinical 
Clinical manifestations of symptoms attributable to MS consist of relapses or disability 
progression. Relapses are historical or current signs and/or symptoms* typical of 
inflammatory demyelination of CNS, lasting at least 24 hours, in the absence of infections 
and/or fever (Lublin and Reingold, 1996). Disability progression refers to a gradual 
worsening of neurologic signs and/or symptoms compatible with CNS demyelination (Lublin 
and Reingold, 1996). 
Relapses can demonstrate DIS when symptoms and/or signs are attributable to different sites 
of CNS. Relapses can demonstrate DIT when occurring at a least 1 month one from each 
other. 
*at least one relapse must be supported by compatible neurological signs and/or 
neurophysiology and/or MRI. 
MRI 
Since about three decades MRI represents the key tool in MS diagnosis and follow-up (FU), 
being also ultimately used in clinical trials. MS lesions appear hyperintense in T2 MRI 
sequences and gadolinium (Gd) enhancement in T1 allows the visualization of lesions with 
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active inflammation. Black holes (BH) are those MS lesions appearing hypointense in T1-
weighted MRI.  
MRI criteria for DIS are based on Swanton 2006 and 2007 (Swanton et al., 2006, 2007) as 
follow: 
• At least 1 T2 lesion in at least 2 of 4 following areas of the CNS: periventricular, 
juxtacortical, infratentorial, spinal cord. 
• If a subject has a brainstem or spinal cord syndrome, the symptomatic lesions are 
excluded from the criteria and do not contribute to lesion count. 
MRI criteria for DIT are based on Montalban 2010 (Montalban et al., 2010), as follow: 
• A new T2 and/or Gd-enhancing lesion on FU MRI, with reference to a baseline scan, 
irrespective of the timing of the baseline MRI 
• Simultaneous presence of asymptomatic Gd-enhancing and non-enhancing lesions at 
any time 
T1-hypointense lesions are not included in the diagnostic criteria for MS. 
CSF exam 
Despite highlighting the importance of the CSF exam regarding differential diagnosis and 
prognosis, the 2010 revision of MacDonald criteria considered it only for the diagnosis of 
PPMS. 
The CSF exam is considered positive if elevated IgG index or 2 or more OB are present 
(Andersson et al., 1994; Link and Tibbling, 1977).  
Evoked potentials 
The 2010 revision of MacDonald criteria didnt consider evoked potentials for the diagnosis 
of MS, apart from using the positivity of visual evoked potentials to corroborate a relapse 
with visual disturbance. 
MS treatment 
Treatment of relapses 
High doses of steroids are widely used to treat MS relapses. This treatment aims to shorten 
the length of symptoms and is not considered as curative of relapses. Accordingly, this 
treatment should be offered only if symptoms provoke significant distress to the patient or 
causing limitation in activities. Considering the different dosing regimen and route of 
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administration, a recent Cochrane was carried out (Burton et al., 2012), finding that there is 
no significant advantage in using IV steroids versus oral, either in clinical or radiological 
outcomes at 4 weeks. Regarding the dosing, 4 over the 5 studies considered adopted either 1g 
of IV methylprednisolone (MP, for 5 days) or 1.4g of oral MP (bioequivalent to 1000 mg 
IVMP). The National Institute for Health and Care Excellence (NICE) recommends to use 
oral MP 0.5g daily for 5 days and if this regimen is not tolerated, failed or the patient needs 
admission to hospital, to consider IVMP 1g of for 3-5 days (NICE guidelines GC186). 
Disease modifying treatments 
The trials performed on MS subjects reporting the results of new disease modifying 
treatments (DMT) are shown in Table 1.1. 
Interferons 
Betaferon, IFNβ1b, is administrated subcutaneously every other day at the dose of 250 µg. It 
was shown to be effective for the treatment of RRMS, SPMS with active disease and within 
12 months of a single demyelinating event (CIS) when MRI evidence predicts a high 
likelihood of recurrent episodes. 
The trials on which its clinical effectiveness is based for RRMS (The IFNB MS Study Group, 
1995; 1993), also report the most common side effects, which are in common with all the 
others interferons. Two trials were carried out to explore its clinical effectiveness for SPMS, 
the first European (European Study Group on interferon beta-1b in secondary progressive 
MS, 1998; Kappos et al., 2001) with positive results on disease progression; the second North 
American (Panitch, 2004) didnt show any significant delay in disability progression. The 
clinical effectiveness for CIS is based on the BENEFIT study (Kappos et al., 2006, 2009). 
Avonex, IFNβ1a, at is administrated intramuscularly once a week at the dose of 30µg. It is 
licensed for the treatment of RRMS, SPMS and CIS with an active inflammatory process. Its 
clinical effectiveness for RRMS and SPMS is based on the results of the MSCRG trial 
(Jacobs et al., 1995, 1996). The trial on which its clinical effectiveness for CIS is based is the 
CHAMPS (Jacobs et al., 2000). 
Rebif, IFNβ1a, at is administrated subcutaneously at the dose of 22 or 44µg once or three 
times a week. It is licensed for the treatment of RRMS or CIS with an active inflammatory 
process. The trial PRISMS reported its clinical effectiveness for RRMS (PRISMS Study 
Group, 1998). The trials on which its clinical effectiveness for CIS is based are the ETOMS,  
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Molecule Dose - administration 
route 
CDMS risk versus 
placebo (duration 
years) 
ARR or relapse number 
reduction versus placebo  
(duration years) 
Progresison active 
treatment versus placebo  
(duration years) 
T2 LL active treatment 
versus placebo 
(duration years) 
T1 Gd+ active treatment 
versus placebo (duration 
years) 
IFNβ1b 250µg every other day 
- SC 
0.50 - HR (2)   -206.0 vs -93.0mm3 (2) 0.0 vs 2.0 (2) 
250µg every other day 
- SC 
 -30% (5) ns 3.6 vs 30.2mm2 (5) NK 
250µg every other day 
- SC 
 0.42 vs 0.57 (2) 0.64 vs 0.53 (survival rate for 
sustained progression) (2) 
  
IFNβ1a 30µg once a week - IM 0.56 - RR (3)   28 vs 313 mm3 (3) 0.4 vs 1.4 (1.5) 
30µg once a week - IM  0.61 vs 0.90 (2) 21.1 vs 33.3% (patients with 
sustained progression) (2) 
-13.2 vs -6.5% (ns)  (2) 29.9 vs 42.3% (2) 
22 µg once a week - SC 0.61 - OR (2) 0.33 vs 0.43 (2)  -487 vs -299mm3 (2) ns 
22 or 44 µg 3 times a 
week - SC 
 0.91-0.86 vs 1.28 (-27; -
33%)v(2) 
 -1.2; -3.8% vs 10.9% (2) -67; -78% (2) 
44µg 1 or 3 times a 
week - SC 
0.53; 0.48 HR (2) -
47; -52% 
    
Glatiramer 
acetate 
20mg once daily - SC 0.55 - HR (3)     
20mg once daily - SC  0.59 vs 0.84 (-29%) (2) ns 1.7 vs 3.0ml - 9 months -10.8% (2) 
Teriflunomide 14mg once daily - oral  0.32 vs 0.50 (-36.3%) (2)  31.5% risk of sustained 
disability (2) 
0.72 vs 2.21ml (2) -80.4% (2) 
Dimethylfumarate 240mg twice daily - 
oral 
     
Fingolimod 0.5mg once daily - oral  0.18 vs 0.40 (-54%) (2) 17.7 vs 24.1% confirmed 
probability of disability 
progression (2) 
3303 vs 3416mm3 (2) 0.2 vs 1.1 (-82%) (2) 
Natalizumab 300mg every 28th day - 
IV 
 0.17 vs 0.36 (-53%) - 2 
years 
0.62 vs .87 (-38%) confirmed 
progression - 2 years 
NK 0.1 vs 1.8 (-90%) - 2 years 
Mitoxantrone 12g/m
2
 ba every 3 
months - IV 
 0.27 vs 0.85 (-68%) (2) -0.13 vs 0.23 EDSS change (2) NK 0.0 vs 16 of patients (2) 
Azathioprine 1-3mg/Kg per day - oral  0.26-AZA vs 0.39-IFNβ 
(2)ns 
-0.08-AZA vs 0.22-IFNβ (2) ns NK 0.20-AZA vs 0.40-IFNβ (2) 
ns 
Alemtuzumab First course: 12 mg/day 
for 5 days - IV 
Second course: 12 
mg/day for 3 days - IV 
 -54.9% vs Rebif44 (2) -30.0% vs Rebif44 (2) -9.3% vs -6.5% Rebiff44 
ns (2) 
7% vs 19% Rebiff44 
positive pts (2) 
37 
 
Table 1.1. Disease modifying treatments for MS. CDMS: conversion to definite multiple sclerosis; 
ARR: annualised relapse rate; LL: lesion load; Gd: gadolinium; IFN: interferon; SC: subcutaneous; 
NK: not known; HR: hazard ratio; OR odds ratio; IV: intravenous; AZA: azathioprine; EDSS: 
Expanded Disability Status Scale. References are reported in the dedicated paragraphs. 
 
at the dose of 22µg once a week (Comi et al., 2001a), and REFLEX, at either 44µg one or 
three times a week (Comi et al., 2012). 
The IFNβ mechanism of action is pleiotropic, affecting many cellular pathways involved in 
the immune activity. Briefly, IFNβ was shown to (i) reduce the matrix metalloproteinases in 
serum (Haghikia et al., 2013; Wu et al., 1999); (ii) interfere with IL-10 and IL-17 pathways 
(Kvarnström et al., 2013); (iii) influence expression of several genes, such as nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2), energy metabolism and antiviral response genes (IKK and 
IKBE) (Croze et al., 2013); (iv) affect monocytes and macrophages activation and cytokine 
production (Brendecke and Prinz, 2012); (v) suppress Th17 in EAE (Galligan et al., 2010); 
(vi) inhibit the CD4 cells from RRMS patients in producing IFNγ and interfering with CD4 
and CD8 cells cytokines production (Kovarik et al., 2007; Skrzipek et al., 2012); (vii) 
increase the production of IL-27, which is a negative inducer for naïve CD4 cells to Th17 
(Prinz and Kalinke, 2010); interfere with the CD4 cells mithocondrial metabolism reducing 
the activity of iATP, sensitive measure of T cell activation (Haghikia et al., 2014). 
Glatiramer acetate 
Glatiramer acetate (GA) is used as DMT in RRMS and CIS courses. The clinical efficacy on 
RRMS were explored in a trial (Johnson et al., 1995, 1998), which also reports the most 
common side effects, while the MRI results are reported by Comi and coll. (Comi et al., 
2001b). The trial on which its clinical effectiveness for CIS is based is the PreCISe (Comi et 
al., 2009). It is administrated subcutaneously 20mg once daily. 
GA is a synthetic polypeptide made up with 4 amino acids (aa), the most common in the 
MBP, with a total length of 45-100 aa. It is therefore designed to be a synthetic analogue of 
MBP. Because of the huge variability of the compound, it can have a great number of 
potential epitopes. It was found to interfere with several functions of the immunity, both 
innate (Benczur et al., 1980; Chabot et al., 2002; Flodström et al., 2002; Jezewska et al., 
1985; Jung et al., 2004; Pul et al., 2011, 2012; Stasiolek et al., 2006; Vieira et al., 2003) and 
adaptive (Aharoni, 2013; Aharoni et al., 1997, 1998, 1999, 2010; Basile et al., 2006; Begum-
Haque et al., 2011; Brenner et al., 2001; Duda et al., 2000; Gran et al., 2000; Hong et al., 
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2005; Kala et al., 2011; Teitelbaum et al., 2003; Tennakoon et al., 2006), further to the effects 
on mechanisms implicated in neurodegeneration (Aharoni et al., 2005; Azoulay et al., 2005; 
Benner et al., 2004; Blanco et al., 2006; Chen et al., 2003; Kipnis et al., 2000; Laurie et al., 
2007; Ziemssen et al., 2002). 
Teriflunomide 
Teriflunomide is accepted for the treatment of adults with active RRMS course, defined as at 
least 2 clinically significant relapses in the previous 2 years, only if patients dont have highly 
active or rapidly evolving severe RRMS, defined as two or more disabling relapses in one 
year, with at least one Gd-enhancing T1 lesion or significant increase of T2 lesions at MRI 
(NICE technology appraisal guidance [TA303]). 
The clinical effectiveness is based on 3 phase III trials, TEMSO, TENERE, TOWER 
(Confavreux et al., 2014; OConnor et al., 2011; Vermersch et al., 2014; Wolinsky et al., 
2013), where also the most common side effects are reported. It is administered orally at 
14mg once daily. 
Teriflunomide inhibits the tyrosine kinase through the inhibition of the dihydroorotate 
dehydrogenase. This is cause of blockage of T and B cells clonal expansion and consequent 
reduction of antibody production (Bruneau et al., 1998; Fox et al., 1999; Greene et al., 1995; 
Ullrich et al., 2001). 
Dimethyl fumarate 
Dimethyl fumarate is accepted for the treatment of adults with active RRMS course only if 
they do not have highly active or rapidly evolving severe RRMS (NICE technology appraisal 
guidance [TA320]). 
The clinical effectiveness is based on the DEFINE (Gold et al., 2012) and CONFIRM (Fox et 
al., 2012) trials, where also the most common side effects are reported. It is administered 
orally at 240mg twice daily. 
Its first mechanism of action involves the activation of the Nrf2 antioxidant response 
pathway, which represents the primary cellular defence against the cytotoxic effects of 
oxidative stress (Linker et al., 2011; Scannevin et al., 2012). This is meant to have 
neuroprotective effects through the inhibition of toxic oxidative stress. The second 
mechanism of action induces the switch from Th1 to Th2 (Litjens et al., 2004; Vandermeeren 
et al., 1997) through the activation of the NF-kB pathway (de Jong et al., 1996; Kolenko et 
al., 1999; Treumer et al., 2003), which also reduces the B cells activation (Marsden and 
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Strasser, 2003) and DC differentiation, regulating their apoptosis (Rescigno et al., 1998; Zhu 
and Mrowietz, 2001). 
Fingolimod 
Fingolimod is a second line oral treatment, given at 0.5mg once daily, for active RRMS 
(NICE technology appraisal guidance [TA254]). 
Its clinical efficacy in RRMS patients is provided by the FREEDOMS and TRANSFORMS 
trials (Cohen et al., 2010b, 2010b), where also the most common side effects are reported. 
The mechanism of action is due to its interaction with the sphingosine 1-phosphate (S1P) 
receptors, present mostly on lymphocytes. Binding to S1P receptors, Fingolimod interferes 
with lymphocytes migration, recruiting from circulation and confining them in the lymph 
nodes (Matloubian et al., 2004) and regulates lymphocytes proliferation and survival (Spiegel 
and Milstien, 2003). Its ability to maintain lymphocytes in lymph nodes is also due to the 
presence of S1P receptors on the endothelium (Jo et al., 2005; Sanna et al., 2006; Wei et al., 
2005). However, lymphocytes still remain reactive to systemic infections, so that the ultimate 
effect of Fingolimod is immunomodulation, rather than immunosuppression (Brinkmann et 
al., 2002; Matloubian et al., 2004; Schwab et al., 2005). 
Natalizumab 
Natalizumab is a monoclonal antibody accepted for the treatment of rapidly evolving severe 
RRMS, defined as two or more disabling relapses in one year, with at least one Gd-enhancing 
T1 lesion or significant increase of T2 lesions at MRI (NICE technology appraisal guidance 
[TA127]). It is administered by IV infusion every 28 days at the dose of 300mg. 
Its clinical efficacy in RRMS patients is provided by the AFFIRM and SENTINEL trials 
(Polman et al., 2006; Rudick et al., 2006)(Polman et al., 2006, Rudick et al., 2006), where 
also the most common side effects are reported. 
Natalizumab exerts its action by binding and blocking the VLA-4, which is an integrin dimer 
composed of two chains, the α4 (CD49d) and β1 (CD29), present on most leukocytes but not 
on granulocytes. The CD49d, target of Natalizumab, is also part of LPAM-1 (α4-β7) which, 
binding to MAdCAM-1, the mucosal vascular addressin cell adhesion molecule present on 
endothelium, represents the main mechanism of action of Natalizumab in Chron disease. The 
block of the α4 chain part of VLA-4 represents instead the main mechanism of action in MS. 
When active (Campbell et al., 1998), the VLA-4 binds the integrin receptor VCAM-1, 
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expressed on endothelial cells, allowing the transmigration of T cells through the BBB 
(Engelhardt and Ransohoff, 2012). 
Mitoxantrone 
Mitoxantrone is an immunosuppressant treatment used for MS only in some European 
countries and US. It is effective in aggressive RRMS, used especially as induction before 
starting DMTs, and in SPMS. It is administered by IV infusion at the dose of 12g/m
2
 of body 
area every 3 months for 2 years. 
Its efficacy on RRMS is based on 3 studies, the first (in which the dose was 8 g/m
2
), further 
the effects on the relapse rate, also showed the Mitoxantrone effective in delaying the disease 
progression (Millefiorini et al., 1997); the second (dose 20mg plus 1g of MP, monthly) 
confirmed the results of the first (Edan et al., 1997); the third (only higher dose between 5 
and 12g/m
2
 of body area every 3 months was convincingly effective) was performed on 
patients with worsening RRMS or SPMS and confirmed the effect in reducing accumulation 
of disability (Hartung et al., 2002). A recent Cochrane reported a significant effect of 
Mitoxantrone in reducing the progression and relapse rate in worsening RRMS, PR (primary 
relapsing) MS and SPMS patients (Martinelli Boneschi et al., 2013). 
Mitoxantrone is an inhibitor of the type 2 telomerase which, by interposing between the DNA 
bases, impairs the synthesis of DNA and its repair (Mazerski et al., 1998). Used as an 
antineoplastic drug, it affects both cancerous and normal cells, especially on the ones with 
higher replication rate, among which lymphocytes. The last trial (Hartung et al., 2002), in 
which two doses were tested, also described the dose-dependent adverse events. 
Azathioprine 
Azathioprine is an immunosuppressant used for treatment of RRMS and SPMS. It is 
administered orally at a variable dose 1-3mg/Kg per day. Several studies support its clinical 
efficacy in MS patients (including a Cochrane), showing a reduction of relapse rate similar to 
interferons and a delay in clinical progression (British and Dutch Multiple Sclerosis 
Azathioprine Trial Group, 1988; Casetta et al., 2007; Ellison et al., 1989; Goodkin et al., 
1991; Lus, 2004; Massacesi et al., 2014; Milanese et al., 1993). 
The most common side effects consist of hypersensitivity reactions, dose-dependent bone 
marrow suppression and liver impairment. 
Azathioprine works by inhibiting the synthesis of purines (adenine and guanine), thus 
impairing the DNA synthesis and its repair (Maltzman and Koretzky, 2003). Like 
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Mitoxantrone, it therefore used as an antineoplastic drug and affects cell populations with 
high replication rate, among which lymphocytes. 
Alemtuzumab 
Alemtuzumab is accepted for the treatment of RRMS in adults with active RR course (NICE 
technology appraisal guidance [TA312]).  
The clinical effectiveness is based on the CARE-MS I and CARE-MS II phase III trials 
(Cohen et al., 2012; Coles et al., 2012), where also the most common side effects are 
reported. They show a reduction of the relapse rate and disability accumulation at 6 years. 
Alemtuzumab is administered in two courses: the first consist in 5 consecutive days at 12 
mg/day, the second in 3 consecutive days at the same daily dose, one year after the first 
treatment course. 
Alemtuzumab is a monoclonal antibody binding the CD52, a glycoprotein present on the 
surface of mature lymphocytes and fund also on monocytes and DC. Binding to the CD52, 
alemtuzumab causes a complement- and antibody- mediated cytolysis, inducing a resetting 
of the lymphocytic population (Coles et al., 1999). 
The in vivo imaging of activated microglia 
Positron emission tomography (PET) is a functional imaging modality. It is based on the 
statistical reconstruction of signals arising from a positron emitter isotope that labels the 
selected compound. PET use extends from blood flow and metabolic rates studies to receptor 
binding. In the latter case, the selected compounds are molecules which bind to a specific 
target. By using PET is therefore possible to visualise a specific biological function in vivo. 
In this study the target molecule, expression of activated microglia, is the translocator protein 
(TSPO), also called peripheral benzodiazepine receptor (PBR). The TSPO is an 18 kDa 
protein of the outer mitochondrial membrane, part of a multi-protein complex, the 
transduceosome, which by transferring cholesterol from the outer to the inner mitochondrial 
membrane represents the principal site of steroid synthesis regulation. The TSPO is itself 
involved in the regulation of steroidogenesis. In the normal brain the TSPO is expressed at 
very low levels, whereas in several pathological conditions, in particular characterised by 
inflammation and neurodegeneration, it is strongly expressed by activated microglia, 
although the methodology here used is not able to distinguish between the TSPO expressed 
by resident activated microglia and possible CNS-infiltrating macrophages. Other possible 
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cellular sources of TSPO are mainly represented by astrocytes. The expression of TSPO by 
different cell populations is discussed in more details in the appendix. 
There are several TSPO ligands which have been developed to use as PET tracers 
(Schweitzer et al., 2010; Trapani et al., 2013). Among them, the PK11195 (PK), 
11
C labelled, 
is the tracer with a longer history of use and at the moment is the most reliable tracer for the 
study of activated microglia, both for its pharmacokinetic-dynamic properties and for the 
availability of fully developed and verified algorithms for the input function. The R- 
enantiomer form of PK was preferred to the racemic because of its two-fold affinity (Shah et 
al., 1994). The best kinetic plasma input model for PK was described by Kropholler and coll. 
as the 2-tissue compartments, 4-rate-constants model (Kropholler et al., 2005). On the basis 
of the kinetic described, Turkheimer and coll. introduced a reference region modelling 
combined with supervised reference tissue extraction, which showed a robust and 
reproducible quantitative assessment of PK in the human brain studies (Turkheimer et al., 
2007; Yaqub et al., 2012). This input function has been used in all the experiments here 
reported. From the mid-1980s, PK represented the only TSPO binding tracer consistently 
used to investigate neuroinflammation. Only recently, aiming higher affinity and lower 
signal-to-noise ratio, the so called second-generation TSPO tracers were developed 
(Chauveau et al., 2008).  
Up to date, nine PET studies explored the microglia activation in MS patients using 
radiotracers binding the TSPO (Table 1.2). Vowinckel used the PK-PET imaging to study 
two MS patients, the first with a relapse corresponding to one active lesion visible at MRI 
occurred 4 weeks before the PET scan, the second with clinical and MRI-inactive MS. 
Increased PK binding was found only in the MRI-active lesion of the first patient, which at 
the time of the PET scan was no longer Gd-enhancing. No increase was reported in the 
patient without active lesions (Vowinckel et al., 1997). Banati studied 12 MS and 8 healthy 
controls (HC) with PK-PET imaging. Higher binding in MS compared with HC was found in 
brainstem and thalami. In the following MRI-defined ROIs, PK binding showed a 
respectively decreasing colocalization: Gd-enhancing, T2 hyperintense and T1 hypointense 
lesions. A correlation between the PK binding in T1 hypointense lesions and EDSS is also 
reported. Increased binding was found in neuronal projection areas corresponding with 
clinical deficits, such as lateral geniculate bodies in subjects with history of optic neuritis 
(ON) and medial longitudinal fasciculus in a patient with internuclear ophtalmoplegia (Banati 
et al., 2000). Debruyne studying 22 MS patients with PK-PET imaging, described a higher 
PK binding in Gd-enhancing lesions compared with NAWM; in T2 lesions of patients with 
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evidence of disease activity (clinically or MR based) the PK binding was higher than in those 
with absence of disease activity. Furthermore, the PK binding in NAWM correlated to the 
disease duration, whereas the binding in GM had the same correlation only when the patients 
with higher disability were considered (Debruyne et al., 2003). Versijpt and coll. performed 
PK-PET imaging on 22 MS patients. They found brain atrophy having a positive correlation 
with the PK binding in NAWM and a negative correlation with the PK binding in T2 lesions 
(Versijpt et al., 2005). Vas and coll. explored the binding potential of PK and 
[
11
C]vinpocetine in 4 MS subjects. Both ligands, with higher binding values for the latter, 
showed increased binding in the regions of local brain damage (Vas et al., 2008). Oh and coll. 
used a second generation tracer, the [
11
C]PBR28, performing PET imaging in 11 MS and 7  
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Author Subjects Tracer Main results 
Vowinckel et al. 1997 2 MS [
11
C]PK11195 Increased binding in MRI-active lesion 
Banati et al. 2000 12 MS; 8 HC [
11
C]PK11195 Increased binding in focal lesions, NAWM and central NAGM 
Debruyne et al. 2003 22 MS; 7 HC [
11
C]PK11195 Increased binding in Gd-enhancing lesions compared with NAWM; T2 lesions 
with higher binding in subjects with evidence of disease activity 
Versijpt et al. 2005 24 MS; 8 HC [
11
C]PK11195 Brain atrophy correlated with PK binding in NAWM; brain atrophy negatively 
correlated with PK binding in T2 lesions 
Vas et al. 2008 4 MS [
11
C]PK11195 and 
[
11
C]vinpocetine 
Both tracers displayed increased binding in regions of focal brain damage; 
vinpocetine had higher binding than PK 
Oh et al. 2010 11 MS; 7 HC [
11
C]PBR28 Increased binding in WM/GM ratio in MS vs HC; increased binding in Gd-
enhancing lesions; global binding correlated with disease duration 
Ratchford et al. 2012 9 MS [
11
C]PK11195 Binding in RRMS patients after one year of GA treatment was globally 
reduced and in particular in cortical GM and cerebral WM 
Takano et al. 2013 9 MS; 5HC [
18
F]FEDAA1106 No different binding across the two populations studied (RRMS and HC) 
Rissanen et al. 2014 10 MS; 8 HC [
11
C]PK11195 Binding in NAWM and thalamus was increased in SPMS vs HC subjects 
Colasanti et al. 2014 11 MS; 11 HC [
18
F]-PBR111 Increased binding in WM lesions and perilesional WM compared with HC; 
higher binding in regions with reduced MTR compared with normal-MTR 
regions; the lesional WM binding correlated with the MS severity score 
 
Table 1.2. In vivo PET studies on activated microglia in MS. Abbreviations: MS = multiple sclerosis; MRI = magnetic resonance imaging; NAWM = normal 
appearing white matter; NAGM = normal appearing grey matter; Gd = gadolinium; HC = healthy controls; RR = relapsing-remitting; GA = glatiramer 
acetate; PBR = peripheral benzodiazepine receptor. 
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HC. They found increased binding in WM/GM ratio on MS vs HC (neither WM nor GM 
alone were significantly different), in Gd-enhancing lesions and perilesional T1-hypointentity 
and the global binding correlating with disease duration. Interestingly, they reported 
increased uptake in some regions which presented, one month later, Gd-enhancement (Oh et 
al., 2011). Ratchford performed PK-PET on nine RRMS patients before and one year after 
treatment with GA. They found reduced global PK binding, in particular in cortical GM and 
cerebral WM, whereas in T2 lesions this change was not reported. Only the patient with the 
highest baseline PK binding experienced relapses during the study period (Ratchford et al., 
2012). Takano and coll. used [
18
F]FEDAA1106 as PET radiotracer, on nine MRI and 
clinically active RRMS patients and five HC. The tracer binding values were not different 
across the two populations studied (Takano et al., 2013). Rissanen and coll. performed PK-
PET imaging on ten SPMS and eight controls. They found an increased PK binding in 
NAWM and thalamus in SPMS vs HC. In patients, NAWM had higher PK binding than T2 
lesions. They also report higher PK binding at the core of Gd-enhancing lesions and at the 
periphery of T1 hypointensities (Rissanen et al., 2014). Colasanti and coll. used a second 
generation tracer for the TSPO, the [
18
F]-PBR111 to study 11 MS and 11 HC. They found 
increased binding in WM lesions and perilesional WM compared with HC. According to the 
MTR alteration, they reported higher binding in regions with reduced MTR compared with 
normal-MTR regions. The increase in the lesional WM correlated with the MS severity score. 
Focal increased binding corresponding to WM lesions was found in clinically active patients, 
whereas in clinically benign subjects this association was not present (Colasanti et al., 2014). 
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CHAPTER 2: RATIONALE AND AIMS 
Rationale 
There is growing evidence that activated microglia play a major role in the pathology of MS 
from very early on after disease onset (Andersson et al., 2008; Carson, 2002; Mack et al., 
2003; Napoli and Neumann, 2010; Piccio et al., 2007). Microglia activation is part of all 
inflammatory processes, being the first line defence for the CNS. Activated microglia 
contributes to MS lesion development, in particular to global WM inflammation and 
neurodegeneration, through phagocytosis, antigen presentation, epitope spreading and 
secretion of cytokines, proteinases and oxidative radicals (Gandhi et al., 2010; Herz et al., 
2010). Nevertheless, once over-activated microglia can remain in this state causing a 
relentless microglia-mediated neurotoxicity (Gao et al., 2003; Huh et al., 2003; McGeer et al., 
2003). In post mortem studies in MS brain activated microglia were found in focal WM 
lesions, diffuse WM injury and cortical lesions (Kutzelnigg et al., 2005). Furthermore, 
activated microglia were more prominent in cortical areas adjacent to lymphoid-like 
structures and meningeal inflammation (Howell et al., 2011; Magliozzi et al., 2007; Serafini 
et al., 2008). 
In keeping with the evidence supporting the role of microglia in the MS pathogenesis, by 
using the PK-PET I expect to find microglia activity in the early stages mainly as a marker of 
inflammation. In later stages, and in particular in progressive patients, where 
neurodegeneration is the major pathological finding with irreversible accumulation of 
disability, microglia activity may represent a marker of inflammatory neurodegeneration. 
Both in early and late stages higher levels of activated microglia may represent predictors of 
worse prognosis. 
Aims 
This project had three principal aims: 
Aim 1. To assess the PK binding in a specific type of MS lesions, the BH, which are lesions 
appearing hypointense in T1 MRI imaging. My aim is to investigate possible association 
between the PK binding in these lesions, clinical disability and its outcome. 
Aim 2. To assess the presence and patterns of microglia activation in the NAWM of CIS and 
MS subjects. Data analysis for comparisons between CIS subjects, MS patients and HC is 
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used to identify possible prognostic parameters for disease severity across all the courses and 
in CIS subjects the subsequent conversion to MS. 
Aim 3. The GM is known as one of the first brain structures affected in MS and particularly 
involved in later stages of the disease, and has a major role in determining patients clinical 
disability. In the third study, my aim is therefore to assess the PK binding in the cortical and 
central GM regions of CIS and MS subjects, in order to evaluate a possible association 
between microglia activation in GM structures and patients disability and outcome. 
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CHAPTER 3: General methods 
Study design 
Study population 
For this project the following populations have been enrolled: 
A. MS subjects: 20 subjects 
 A1. Relapsing: 11 subjects 
 A2. Progressive: 9 subjects  
B. CIS: 18 subjects 
C. HC: 8 subjects 
Twenty patients affected by MS, 11 relapsing and 9 progressive (Lublin and Reingold, 1996), 
were recruited during normal NHS neurology clinic FU. Eligible subjects were aged 18 to 60 
years and diagnosed with MS according with the McDonald criteria (Polman et al., 2005).  
Eighteen subjects with a diagnosis of CIS who presented with symptoms indicating ON, 
spinal cord or brainstem syndrome were recruited from NHS neurology clinics within ten 
months of symptoms onset. 
Eight HC aged 18 to 60 years and with no history of neurological disease were recruited with 
the aid of posters exposed at the Imperial College Hospitals, mentioning financial reward. 
On receiving fully informed consent according to the Declaration of Helsinki, subjects were 
enrolled. 
Exclusion criteria included patients that have experienced a relapse or have been treated with 
steroids (IV and/or oral) within 1 month. 
Tables with the study population demographic and clinical characteristics have been included 
in the dedicated chapters, according to the subjects considered for each study, apart from the 
HC, shown in Table 3.1.  
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Subject 
Age 
(years) 
Gender 
HC 1 29.0 M 
HC 2 37.9 M 
HC 3 28.1 F 
HC 4 28.0 F 
HC 5 25.0 F 
HC 6 27.9 F 
HC 7 26.2 M 
HC 8 39.9 F 
Mean (SD) 30.2 (5.5) 5F/3M 
Table 3.1. Healthy control (HC) population demographic and clinical characteristics. SD: 
standard deviation; F: female; M: male. 
Clinic-based assessments 
All the patients and HC underwent the following clinical assessments: 
- History: a structured clinical interview, MS history with past and actual treatment, 
performed at the Imperial College London clinics. 
- EDSS: a standard clinical neurological examination to grade Kurtzkes Functional 
Systems (FS) and calculate the Expanded Disability Status Scale (EDSS), were performed in 
each visit for each patient at the Imperial College clinics. The Kurtzke FS consists of eight 
single-item scores designed to quantify the results of the neurological examination. It is an 
ordinal index of disability with unequal steps, with scores which vary between 0 and 6. The 
EDSS is calculated on the basis of the FS scores and the patients walking impairment. The 
score varies between 0 (normal neurological exam) and 10 (death due to MS) (Kurtzke, 
1983). 
- MS impact scale (MSIS-29): a self-assessment questionnaire that is used to assess 
disability in patients with MS. It consists of 29 questions on how MS has affected subjects, a 
29-item measure that includes two scales: physical impact (20 items) and psychological 
impact (9 items). The physical and psychological summary scores are generated by summing 
individual items and then transforming these to a 0100 scale. High scores indicate poorer 
health (Hobart et al., 2004). 
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Follow-up 
CIS patients have been followed up every year for 2 years to identify conversion to 
MacDonalds defined MS. The investigations for each visit included: history collection, the 
neurological examination for the EDSS scoring, the administration of MSIS-29 and a Gd-
enhancing MRI scan. 
Imaging studies performed 
All the patients and HC attended the MRC cyclotron unit at Hammersmith Hospital, Imperial 
College London, for a PK-PET scan, and the Imaging Department Charing Cross Hospital, 
Imperial College London for a co-localizing Gd-enhancing MRI scan. 
PET and MRI scans were performed to all the subjects in a 7 days temporal window. 
The study received the Hammersmith and Queen Charlottes Research Ethics Committee 
ethical approval and the Administration of Radioactive Substances Advisory Committee 
permission to administrate the PK. 
Materials 
MRI imaging 
A clinical 1.5-Tesla MRI system (Siemens MAGNETOM Avanto, Ehrlangen, De) was used 
to perform the MRI scans. Volumetric T1-weighted sequences (coronal and axial T1-spin 
echo: TR=635 ms, TE=17 ms, 5 mm slice thickness); T1 volumetric magnetization-prepared 
rapid acquisition with gradient echo - MPRAGE - TR=1900 ms, TE=3.53 ms, TI=1100 ms, 
flip angle 15°, 1 mm isotropic voxels) pre- and post IV bolus Gd chelate administration (7.5 
mmolgadobutrol) and T2-weighted sequences (axial T2-spin echo: TR=4540 ms, TE=97 ms, 
5 mm slice thickness; axial FLAIR: TR=9000 ms, TE=114 ms, TI=2500 ms, 5 mm slice 
thickness) were acquired for the purposes of image registration, to allow the localization of 
the ROIs, to define their lesion load and perform volume analysis. MRI images were re-
orientated with the horizontal line defined by the anterior  posterior commissures (ACPC) 
line and the sagittal planes parallel to the midline. 
PET imaging 
The Discovery RX PET/CT scanner, which is a lutetium yttrium orthosilicate (LYSO) based 
system with crystals of 4.2 x 6.3 x 30 mm
3
, has been used for the PET scanning. Its transaxial 
resolution for 2D and 3D is respectively 5.1 mm and 5.0 mm full width at half maximum 
(FWHM) at 1 cm from the centre; at 10 cm its radial resolutions are 5.9 mm for both 2D and 
3D, and the tangential resolutions are respectively 5.1 mm and 5.2 mm. The axial resolution 
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at 1 cm for 2D and 3D is respectively 4.8 mm and 5.8 mm FWHM, at 10 cm from the centre 
it is respectively 6.3 mm and 6.5 mm (Kemp et al., 2006). 
The mean injected dose for PK was 365 MBq (range: 320-386 MBq) as an IV bolus; the 
tracer was injected over 10 s then flushed with saline solution over 20 s. Emission data 
generated 18 time frames of tissue data over 60 min (30 s background frame, 1 x 15 s frame, 
1 x 5 s frame, 1 x 10 s frame, 1 x 30 s frame, 4 x 60 s frames, 7 x 300 s frames, and 2 x 600 s 
frames). PK tracer was supplied by Hammersmith Imanetplc, London. 
For each subject the intake of caffeine, drugs, smoking or any specific diet were assessed; 
smoking, affecting the TSPO expression through reactive oxygen species production (Nagler 
et al., 2010), alcohol, because of its effect on plasmatic adrenocorticotropic hormone (Boyd 
et al., 2010) and caffeine, for its effect on microglia activation (Kang et al., 2012) 
consumption was not allowed during the 12 hours before the scanning. Despite 
benzodiazepines are considered medications which dont bind the PBR, considering it 
possible (even if with very low affinity, (Rao and Butterworth, 1997)) they were not allowed. 
However, none of the subjects participating to this study was under treatment with 
benzodiazepines. Eating and drinking was not allowed during the 8 hours before the 
scanning. In the PET scanner, the subjects were positioned supine with their transaxial planes 
parallel to the line intersecting the ACPC line. Their head movements were limited by the 
use of foam holders and detected by a video camera. The resting position was maintained 
during the whole length of the scanning time, in a no noisy and low light room. 
Techniques 
PK PET analyses 
The scans were performed, data acquired and raw images reconstructed and summed to 
produce a dynamic image. This was used to generate an ADD image. Binding potential (BP) 
values were calculated after applying the simplified reference tissue model (SRTM) using the 
reference regions extracted by the supervised clustering algorithm. As input function, the 
SUPERPK software package (Imperial innovations) was used (Turkheimer et al., 2007; 
Yaqub et al., 2012). This is based on SRTM (Gunn et al., 1997) and provides the 
quantification of the non-displaceable binding (PKBPND) (Innis et al., 2007) by the 
generation of tissue references with a supervised analysis of the time-activity curves (TAC) 
kinetics at voxel level. This is a cluster analysis of 4 tissue classes (elaborated from 12 HC 
and 3 patients with Hungtington disease-HD), 2 normal brain parenchymal references (WM 
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and GM), one with pathological binding (defined on the striatum and globus pallidus of HD 
patients) and 1 reference tissues (blood). In this way the clustering algorithm extracts 
automatically a reference tissue region, by taking into account the kinetic curves with a 
known and pre-defined pattern, whereas each pixel TAC is weighted by its normal GM index. 
The correction for vascular binding was performed (Tomasi et al., 2008). The three main 
advantages of this reference region input model consist in heeding the non-specific PK 
binding, of great extent in the brain, in producing BP values very close to the plasma input 
functions and in selecting voxels of GM reference regions that are distant from the 
vasculature, avoiding its kinetic component. 
The PK-PET and MRI images were automatically co-registered by maximization of mutual 
information algorithm in the SPM2 software package. This transformation was also applied 
to the thresholded GM and WM contribution and the 83-ROIs generated with the MAPER 
approach (Heckemann et al., 2010), resulting in all images being registered with the given 
PK-PET image data set. The MRI atlases were then multiplied with the thresholded GM and 
WM contributions producing for each subject in two sets of GM and WM ROIs. The 
resulting BP maps were then sampled using either the whole or the respective GM and WM 
sets of ROIs with the ANALYZE medical imaging software (version 8.1, Mayo Foundation, 
MN, USA). 
For the analysis of specific MS lesions or anatomical regions not included in the atlases the 
ROIs were manually drawn, specifics are provided in the respective sections. All the ROIs 
were considered in the 3 spatial dimensions, therefore consisting in volumes of interest.  
Statistical analyses 
Statistical analyses were performed using SPSS (Version 17.0) and PRISM (GraphPad 
Software, Inc. Version 6.01 for Windows). For all the variables, the normality of the 
distribution was tested with the Kolmogorov-Smirnov (KS) test, whereas the Shapiro-Wilk 
test was used for small samples (n<5). If normality was satisfied, bivariate correlation was 
tested using Pearson correlation coefficient. If normality was not satisfied, the Spearmans 
rho correlation coefficient was used. The multiple comparison correction was performed 
using the Hochberg correction with the p-plot estimate of the number of null hypothesis 
(Turkheimer et al., 2001). Correlation was considered significant at 0.05 level (2-tailed). 
Differences between two groups were tested using the independent samples t-test, corrected 
when equal variance was not assumed (Welchs correction), according to the Levenes test 
for the equality of variance. When the assumption of normality was not satisfied, the 
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difference between two groups was tested using the independent samples Mann-Whitney U 
Test. The KS test was also used to compare population distributions. The general linear 
model (GLM) for repeated measures was used to analyse the variance of within-subjects 
variables and between-subjects factors. The Greenhouse-Geisser correction was then used to 
test the Region of interest X Group interaction (when significant the Mauchlys test of 
sphericity). 
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CHAPTER 4: Microglia activation in MS Black Holes 
Background 
In MS the MRI demonstrates a variety of changes that have different levels of sensitivity and 
specificity. The current preferred outcomes for phase II trials is based on MRI assessed new 
or increased T2 and Gd-enhancing T1 lesions. However, it is an imperfect aid in the 
understanding of current symptoms and disability and it is limited in predicting outcome 
(Sicotte, 2011). BH are defined as MS lesions appearing hypointense at T1-weighted MRI 
(Truyen et al., 1996). Among all the other MRI-based measures, BH in MS have been 
associated with irreversible disability (Paolillo et al., 1999; Simon et al., 2000; Truyen et al., 
1996; van Walderveen et al., 1999a). However, this finding is not consistent (Giugni et al., 
1997; Masek et al., 2008; ORiordan et al., 1998). Given the inconsistency of imaging-based 
association with clinical correlates, looking at the evidence in pathological studies seeking 
processes underlying BH, a clearer support is not provided. BH were shown to correlate with 
axonal damage (Brück et al., 1997; van Walderveen et al., 1998, 1999b) or not (Bitsch et al., 
2001). Van Walderveen performed a study in biopsied lesions and reported axonal loss and 
extracellular oedema as the factors that mainly affect the degree of hypointensity on T1-
weighted MRI sequences (van Walderveen et al., 1999b). At the opposite with these results, 
Bitsch and coll. reported that a correlation between axonal loss and BH was not found in 
active lesions biopsies from 14 patients with early MS (Bitsch et al., 2001). Finally, in EAE 
T1 hypointensity correlated with cellular infiltrates and demyelination in the lesion centre, 
whereas increased microglial and astroglial activity was found only in the perilesional area 
(Nessler et al., 2007).
 
I explored the hypothesis that PK-PET scan could provide evidence supporting the clinical 
role of microglia activation in MS BH, supported by the large body of evidence showing a 
major role for activated microglia in the pathology of MS (Gao and Tsirka, 2011). This is 
reported in early focal WM lesions, where activated microglia are found in increased 
numbers alongside blood derived macrophages (Breij et al., 2008). This is also reported in the 
later progressive stages of MS, where chronically activated microglia are associated with 
diffuse activation and axonal damage throughout the WM (Kutzelnigg et al., 2005, Howell et 
al., 2010), neurodegeneration and regions of meningeal inflammation in the GM (Magliozzi 
et al., 2010). 
55 
 
Specific methods 
ROIs analyses - T1 black holes 
ROIs were manually drawn, generating BH maps for each subject, from which both the 
volume and the PKBPND were calculated. BHs were defined as hypointense regions, with 
volume > 3 mm
3
, on T1-weighted MRI images corresponding to hyperintense regions on T2-
weighted images (Truyen et al., 1996). 
Results 
Study population 
The population included for this study is shown in Table 4.1. Nineteen patients affected by 
MS, 10 with relapsing and 9 with progressive course were included. The relapsing and 
progressive patients had respectively a mean (±SD) age of 38.3 (±8.5) and 39.2 (±11.1) years, 
age at onset of 25.8 (±5.6) and 23.5 (±9.3) and disease duration of 12.6 (±7.3) and 15.8 
(±10.5) years. The progressive group had a length of disease before the onset of progression 
of 7.9 (±7.3) years, with a significantly higher disability at EDSS than the relapsing group 
(7.3 (±1.2) and 5.3 (±1.5) respectively, p=0.004). 
MRI T1 black holes in the MS patients subgroups 
A total of 1,242 BH were identified with a mean (±SD) per patient of 65.4 (±47.8), 672 in the 
relapsing (67.2 (±49.9)), and 570 in the progressive (63.3 (±48.3)) groups. There was no 
significant difference (p=0.866) in the mean number between relapsing and progressive 
groups. None of the BH identified were Gd-enhancing. The BH mean volume was 
197.9±1233.2mm
3
 (with a range of 30.8-20006.3mm
3
). The BH total volume for each subject 
(lesion load), as measured by MRI, did not correlate with any of the clinical or 
demographical variables: disability, age of onset and disease length in the total population or 
in relapsing and progressive groups analysed separately. 
Wide range of PK binding within MRI T1 black holes 
The BH population showed a wide range of PK enhancement. BH were found to show either 
presence (BHPK
+
) or absence (BHPK
0
) of detectable PKBPND (the threshold being the mean 
PKBPND of a ROI = 0) Fig. 4.1 and 4.2 show respectively PK-PET imaging pertaining to one 
relapsing and one progressive patient with coexisting BHPK
+
 and BHPK
0
. 
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Subject Age 
Age at 
onset 
Disease 
duration 
EDSS Course Medication
a
 
MS 1 29.5 25.8 3.6 9.5 SP Cyclophosphamide 
MS 2 31.6 18.6 13.0 4.0 RR None 
MS 3 46.3 21.2 25.1 8.5 SP None 
MS 4 26.1 18.4 7.7 7.0 SP Copaxone 
MS 5 42.0 13.9 28.2 7.0 SP None 
MS 6 33.1 26.1 7.1 8.0 RR Interferon β-1a 
MS 7 47.6 34.4 13.2 4.0 RR None 
MS 8 28.9 25.2 3.8 7.0 SP None 
MS 9 43.5 20.4 23.1 5.5 SP None 
MS 10 57.8 46.5 11.3 6.5 SP None 
MS 11 39.1 25.7 13.4 6.5 RR None 
MS 12 49.4 20.0 29.4 8.0 SP None 
MS 13 25.2 21.8 3.4 4.5 RR None 
MS 14 47.1 27.9 19.2 6.5 RR Copaxone 
MS 15 46.6 35.0 11.6 6.0 RR None 
MS 16 43.7 19.0 24.6 3.5 RR None 
MS 17 42.3 23.3 19.0 4.0 RR None 
MS 18 29.6 19.7 9.9 7.0 PP None 
MS 19 26.8 25.9 1.0 5.5 RR Interferon β-1a 
Mean (SD) 38.8 (9.6) 24.7 (7.5) 
14.1 
(8.9) 
6.2 (1.7) 19 Total  
Mean (SD) 38.3 (8.5) 25.8 (5.6) 
12.6 
(7.3) 
5.3 (1.5) 10 Relapsing  
Mean (SD) 39.2 (11.1) 23.5 (9.3) 
15.8 
(10.5) 
7.3 (1.2) 9 Progressive  
R-P mean 
difference 
ns ns ns *   
Table 4.1. MS population demographic and clinical characteristics, in order of PET scan date 
(from oldest to newest). EDSS: Expanded Disability Status Scale; R-P: Relapsing-Progressive; RR: 
relapsing-remitting; SP: Secondary Progressive; PP: Primary Progressive; 
a
: medication for MS at the 
PET scan; SD: Standard Deviation; ns: non-significant; * p=0.004.  
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Figure 4.1. PK enhancing black hole (BHPK
+
) in one relapsing patient. Axial view of an MRI (A) 
and a PK-PET (B) images. The red arrow points to a BHPK
+
, and the blue arrows to non-enhancing 
black holes (BHPK
0
). The colour scale from top to bottom represents higher (H) to lower (L) 
PKBPND. 
 
Figure 4.2. Black holes PK enhancement heterogeneity. Axial view of fused PK-PET  MRI image 
in a progressive MS subject (A). A closer view of the same image (yellow rectangle in A) shows two 
black holes (BH) on MRI (B) and on fused PK-PET  MRI (C). The BH highlighted in red represents 
an example of non-enhancing BH (BHPK
o
); the BH highlighted in green represents an example of PK 
enhancing BH (BHPK
+
). The colour scale from top to bottom represents higher (H) to lower (L) 
PKBPND. 
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Considering the whole population studied, ~24% of BH were BHPK
0
 with the remainder 
being BHPK
+
. When examined the BH population according to the disease subtype, I didnt 
find any significant difference in number per patient. The BHPK
+
 mean (±SD) per patient 
was 51.0 (±38.2) in relapsing and 48.6 (±41.7) in progressive subjects (p=0.896), whereas the 
BHPK
0
 were 16.2 (±11.9) in relapsing and 14.8 (±10.0) in progressive patients (p=0.783; 
Table 4.2). 
 
Black Holes BHPK
+
 
Number (% of total) 
Mean per patient (±SD) 
BHPK
0 
Number (% of total) 
Mean per patient (±SD) 
Total 
Relapsing 510 (±41.1) 
51.0 (±38.2) 
162 (±13.0) 
16.2 (±11.9) 
672 
Progressive 437 (±35.2) 
48.6 (±41.7) 
133 (±10.7) 
14.8 (±10.0) 
570 
Total  
difference 
947 (±76.2) 
ns 
295 (±23.8) 
ns 
1242 
Table 4.2. Black holes population. BHPK
+
: Black Holes PK enhancing; BHPK
0
: black holes PK 
non-enhancing; SD: standard deviation; EDSS: expanded disability status scale; MS: multiple 
sclerosis; PET: positron emission tomography; FU: follow-up; ns: non-significant. 
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Figure 4.3. Volumetric distribution of the black holes (BH) in percentage in the four groups of 
patients divided by the course (relapsing or progressive) and the PK-PET enhancement, detectable 
(BHPK
+
) and absent (BHPK
0
). X = BH volume (log scale base 10); Y = % of BH. 
Relapsing and progressive patients have different BH volume and PK binding 
I then analysed the BHPK
+
 and BHPK
0
 volumetric distribution between relapsing and 
progressive groups (Fig. 4.3), which didnt show significant difference, respectively p=0.907 
and p=0.387. Analysing the volumetric distribution within relapsing patients, I found a 
significant difference between BHPK
+
 and BHPK
0
 (p=0.027, Fig. 4.4a), with mean, median 
and SD of respectively 114.84 vs 84.61, 40.50 vs 30.75 and 279.53 vs 273.11 mm
3
. The same 
analysis performed in the progressive group was not significant (p=0.347). Considering the 
main interest in the BHPK
+
 population, I further analysed the spectrum of the PK uptake 
(Fig. 4.4b). The progressive patients BHPK+ had higher PKBPND than the relapsing patients 
group, with a significantly different distribution (p=0.00003). The analysis of BH volume and 
PKBPND showed therefore that in relapsing patients the BHPK
0 
were smaller compared with 
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the BHPK
+
 and that the PKBPND in the BHPK
+ 
was lower in relapsing than in progressive 
patients. 
 
 
Figure 4.4. Differences in volumetric and PK binding distribution of black holes (BH). (A) 
Percentage of BH (X-axis) according to their volume in mm
3
 (Y-axis, log scale base 10) in relapsing 
patients. Black line: non-enhancing BH (BHPK
0
); red line: enhancing BH (BHPK
+
). (B) Distribution 
of BHPK
+
 in percentage (Y-axis) according to their PK binding (X-axis), in relapsing (black bars) and 
progressive (red bars) subjects. 
Relapsing patients with lower MRI T1 black holes lesion load show higher PK binding  
Examining the relationship between BHPK
+ 
volume and their PKBPND, according to the 
clinical MS courses, I found a significant inverse correlation between the BHPK
+
 lesion load 
and PKBPND in the relapsing group. This analysis was carried out considering the average of 
PK binding and volume pertaining to this subgroups BHs. A second correlation was 
performed between PK binding and volume for each single subject. One patient clearly 
represented an outlier, having only two BHs, and the second correlation described couldnt be 
performed. This patient was therefore excluded from this analysis. The correlation between 
the average of PK binding and volume in relapsing patients was significant (r=-0.709; 
p=0.033, Fig. 4.5). Relapsing subjects with a smaller BH lesion load had a higher PKBPND. 
The analysis at individual level showed correlation coefficient mean, SD and standard error 
of mean of respectively -0.13, 0.19 and 0.006. 
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Figure 4.5. Correlation PKBPND - volume in black holes (BH) of relapsing patients. Correlation 
between PK binding (PKBPND) in BH (Y-axis) and volume average in mm
3
 (X-axis), each dot 
representing a relapsing MS patient. 
 
Clinical correlate of PK binding in progressive patients MRI T1 black holes  
Given the differences between BH characteristics in relapsing and progressive patients with 
regards to the PKBPND, I explored the possibility of a correlation between the clinical 
disability (EDSS) and the PK-PET binding (PKBPND) in the two MS population. This 
analysis showed a significant correlation between the PKBPND in BHPK
+
 and EDSS in the 
progressive subjects (r = 0.818, p<0.01, Fig. 4.6). The same analysis performed in the 
relapsing group and in the whole population didnt show any significant result. 
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Figure 4.6. Correlation PKBPND in black holes (BH) and EDSS in progressive patients. 
Correlation between PK binding (PKBPND) in BH (Y-axis) and the subjects disability scored with the 
EDSS (X-axis), each dot representing a progressive MS patient.  
Considering the association, in progressive patients, between disability and PKBPND in BH, I 
tested the possibility of a clinical prognostic importance of the PK-PET in this population. 
Performing the EDSS, I re-assessed the disability of the progressive patients at a mean (±SD) 
of 20.9 (±4.1) months (range 17-27) after the PK-PET scan. During this period, as directed by 
their clinical neurologist, this group had been given a range of treatments, including 
copaxone, mitoxantrone, cyclophosphamide, natalizumab, or no treatment. 
Five patients, labelled as Group A, had a stable or increased disability at 20.8 (±5.0) months 
after the PET scan. Four patients, labelled as Group B, showed a slight improvement in their 
disability at 21 (±2.7) months after the PET scan (Table 4.3 reports the baseline 
characteristics of these two populations). I assessed again their disability at a further FU of 12 
months, 32.9 (±4.4) months from baseline, which confirmed the EDSS score. 
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Group A 
Mean (±SD) 
Group B 
Mean (±SD) 
Difference 
Age 41.00 (±10.72) 36.95 (±9.73) ns 
Age at MS onset 25.4 (±12.55) 21.0 (±2.90) ns 
Disease duration 16.26 (±9.06) 16.48 (±11.21) ns 
Years on only relapsing course 4.86 (±5.40) 12.73 (±9.95) ns 
Age at progression onset 29.52 (±13.20) 33.40 (±9.15) ns 
Years on progressive course 11.32 (±7.55) 3.55 (±1.83) ns 
EDSS at baseline (PET scan) 7.70 (±1.12) 6.88 (±0.89) * 
FU time from baseline (months) 20.80 (±4.96) 21.00 (±2.74) ns 
EDSS change + 0.60 - 0.70 
 
Medication 
- Glatiramer 
- Mitoxantrone 
- Cyclohosphamide 
- Natalizumab 
- No treatment 
Number of patients 
0 
0 
2 
1 
2 
Number of patients 
1 
1 
0 
1 
1 
 
Table 4.3. Baseline demographic and clinical characteristics of progressive subjects. Subjects are 
grouped according to their clinical outcome at 2 years follow-up. Group A: n = 5 progressive MS 
patients with stable or increased disability at follow-up; Group B: n = 4 progressive MS patients with 
decreased disability at follow-up; SD: Standard Deviation; EDSS: Expanded Disability Status Scale; 
ns: non-significant; *p=0.0159. 
Having identified these two subgroups of progressive patients according to their outcome, I 
retrospectively analysed their PK-PET scans, finding a significant difference in the BHPK
+
 
BPND. The group A, stable or increased disability, had a mean PKBPND of 17.07 (±7.26) per 
patient, whereas the mean in group B, with improved disability it was 2.52 (±0.94), 
(p=0.0057, Fig. 4.7a). A similar result was also present considering the baseline BH and 
BHPK
+
 volume load. In Group A they were significantly higher compared with Group B, 
respectively p=0.0047 and p=0.0274 (Fig. 4.7b). The same analysis was performed on 
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relapsing patients (who were all started on natalizumab during this period), following them 
up for 36.7 (±8.73) months after PET scan. The retrospective analysis performed on the PK-
PET of this group didnt show any significant difference in PKBPND between group A and 
group B, respectively with a stable or increased disability and improved disability and 
PKBPND 6.08 (±5.82) and 9.27 (±5.71) per patient. 
 
Figure 4.7. Black holes in progressive patients and clinical outcome (X-axis). Group A: patients 
with a stable or increased disability at follow-up (FU). Group B: patients with an improvement of 
disability at FU. Y-axis: PKBPND load (A); BH volume load and BHPK
+
 volume load (B). 
Discussion 
BH represent one of the regions selected to be explored in this wider PK-PET study because 
of the possible clinical relevance and the inconsistent clinico-pathological correlates. The 
results show that there is a great heterogeneity in the PKBPND of the BH. Considering the 
whole MS population, the PKBPND is not correlated to clinical disability or prognosis, 
whereas the PK-PET performed in progressive MS patients show indication of a role for 
activated microglia in subjects disability. This was found both in the correlation between 
baseline PK-PET and disability and in the prognostic value of activated microglia in the 2-
year disability. With regard to the RRMS course, the PKBPND is not associated with 
disability, being also not higher in subjects with worse prognosis, and found to be more 
prominent in smaller BH. This study therefore provides an interesting prompt for further 
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investigations on the role of activated microglia in MS disability and its prognosis, with 
renewed interest in the BH, especially in progressive patients. 
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CHAPTER 5: Microglia activation in NAWM 
Background 
The interest in studying the activated microglia in MS NAWM resides in the known changes 
in this region, despite it is shown to be normal on conventional MRI and gross 
neuropathology. The non-conventional MRI techniques, such as magnetic resonance 
spectroscopy (MRS) and diffusion tensor imaging (DTI), showed alterations in MS NAWM. 
Investigating the neuropathological correlates to these MRI changes, several studies reported 
the presence of activated microglia. With regards to the MRI studies, SPMS subjects have 
significant spectroscopic abnormalities, mainly reduced  N-acetyl aspartate (NAA), in 
comparison to HC and RRMS, evidence of axonal damage in NAWM (Aboul-Enein et al., 
2010; Tourbah et al., 1999). An interesting study by Moll and coll. (Moll et al., 2011) was 
performed using MTR and DTI at different distance from T2 WM lesions, associating their 
signals with histopathology findings. They showed that in NAWM the changes in DTI and 
MTR signals are associated with activated microglia and not with changes in myelin or 
axonal integrity. In CIS subjects axonal damage is reported at NAA-MRS compared with 
controls in NAWM, with a further increase in MS patients (Wattjes et al., 2007). Stromillo 
and coll. found the NAA-MRS significantly reduced also in radiologically isolated 
syndromes (RIS) compared with HC (Stromillo et al., 2013). Finally, Fernando reported 
MTR changes in CIS subjects NAWM compared with controls (Fernando et al., 2005), 
implying a defective integrity of NAWM macromolecular structure. 
With regards to the neuropathology, several studies reported changes in MS NAWM. 
Structurally, Kutzelnigg describes an increasing involvement of the NAWM during the 
evolution of MS, referring to the RR stage as mostly focal in WM involvement and 
progressive stage as interested by diffuse changes in the whole WM, including the normal 
appearing regions (Kutzelnigg et al., 2005). In this study, the microscopical alteration of the 
NAWM were characterised by higher density of activated microglia with formation of 
nodules, increasing across the MS courses. Interestingly, this diffuse involvement of NAWM 
correlated with the GM damage, implying that diffuse alteration of the NAWM are associated 
with higher cortical damage, and likely to disability. The presence of activated microglia in 
NAWM is also reported by De Groot, where the 58% of the macroscopically normal tissue 
sampled was represented by preactive lesions (De Groot et al., 2001)  aggregates of 
microglia in absence of myelin breakdown (Reynolds et al., 2011). The presence of activated 
microglia in preactive lesions (NAWM) is reported by van Horssen to occur in absence of 
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evident BBB disruption (van Horssen et al., 2012). Finally, Howell described the changes in 
NAWM from MS tissue and EAE model, being characterised by the presence of activated 
microglia in correspondence of axo-oligodendrocyte pathology at paranodal and nodal 
domains. The axo-glial disruption, characterised by axonal injury, correlated with the level of 
microglia activation and was independent of demyelination and lymphocytic infiltration, 
paralleling the WM alteration found in PD and preclinical EAE. These pathological changes, 
which persisted in chronic EAE, were reversible with the resolution of microglia activation 
by minocycline (Howell et al., 2010). 
On the functional aspect, studying the molecular pathways active in NAWM, Graumann 
(Graumann et al., 2003a) described the activation of hypoxia-like reaction pathways, in 
which the residing microglia was persistently activated in a way similar to the hypoxic injury 
preconditioning, speculating that this microglia could be a source of reactive oxygen and 
nitrogen species. Melief and coll. (Melief et al., 2013) reported microglia in NAWM being 
alerted (activated) but with a phenotype unresponsive to LPS, thus immunosuppressed. They 
interpreted this condition as reflecting ongoing neuroinflammation, in which microglia were 
at the same time active/alerted, but suppressed to prevent further damage. 
Literature shows therefore that the NAWM is affected possibly since the first clinical episode 
of demyelination and that its pathological involvement increases with the development of the 
disease. A constant pathological feature of the NAWM involvement is the increased levels of 
activated microglia, which also is shown to be higher during the later stages of MS and 
associated with axonal damage, thus likely to disability, independently of demyelination and 
peripheral blood mononuclear cells infiltration. The PK-PET is therefore a promising tool in 
examining the NAWM changes in microglia activation and possible association with 
disability across the several stages of MS. If the NAWM change is detectable in CIS, it would 
be interesting to explore the PK-PET potential in predicting this group conversion to defined 
MS and disability. 
Specific methods 
ROIs analyses 
The ROIs included manually drawn WM lesions, defined as T2-FLAIR hyperintensity and 
identified as demyelinating lesions by myself and an experienced neuroradiologist (Dr. Adam 
Waldman), and NAWM, drawn as far as possible from WM lesions (however further than 
1cm), on at least 3 consecutive T2 slices (!1cm). Eleven NAWM ROIs were drown for each 
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subject, one in each side of temporal, frontal, occipital, parietal lobe and cerebellum and one 
in corpus callosum. A total of 495 ROIs for NAWM were therefore sampled with a mean 
(±SD) volume of 1.58 (±0.86) cm
3
. 
Statistical analyses 
To assess the difference between groups the mean or median were first considered. In 
evaluating difference between groups of patients, using variables measured in multiple 
regions, their distributions were also compared over the several ROIs. In order to explore the 
influence of the different ROIs across groups I then used the GLM for repeated measures 
with ROIs as the repeated factor and Group as a between-subject factor. When the difference 
between groups was not uniform across ROIs, the ROIs effect was also tested. 
The normality of distribution and mean or median difference between two groups were tested 
as specified in the general methods chapter. When more than two groups were considered, 
difference of mean was tested with 1-way ANOVA (and Bartletts test for SD) and median 
with Kruskall-Wallis (KW) test. Multiple comparisons were corrected with Holmes-Sidaks 
test for variables with normal distribution and Dunns correction for variables with not 
normal distribution. The difference of variables distribution across ROIs between two groups 
was tested as specified in the general methods chapter, whereas testing the distribution in 
more than two groups the KW was used instead. The effect of specific ROIs was tested with 
ANOVA or KW as specified above. 
Results 
1. Analysis of the NAWM in CIS population 
I first considered the analysis of CIS subjects, comparing them with the HCs. This was 
directed to explore and highlight the early changes occurring in NAWM at the first episode of 
demyelinating disease. 
Clinical and demographic characteristics of population 
The population is composed by eighteen CIS and eight HC subjects, as shown respectively in 
Tables 5.1 and 3.1. Their age had respectively a mean (±SD) of 38.5 (±7.8) and 30.2 (±5.5) 
years. Within the CIS subjects two had ON, seven a brainstem and eight a spinal cord 
syndrome, one of them had symptoms referable to a hemispheric lesion. They were enrolled, 
examined and underwent MRI and PET scans in 5.3 (±2.6) months from the clinical onset. 
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Sixteen CIS subjects completed the FU at 2 years, the two patients who withdrew felt they 
had no problems. At the 2-year FU five patients had clinically-defined MS. 
Subject Age Gender EDSS 
Time from onset 
(months) 
Type 
McDonald criteria 
at 2 years 
CIS 1 36.5 F 1.5 5 ON N 
CIS 2 37.5 M 3.5 10 ON N 
CIS 3 36.6 F 1.0 4 BS Y 
CIS 4 45.8 M 1.0 4 BS withdrawn* 
CIS 5 31.2 F 1.5 7 HP Y 
CIS 6 53.7 M 2.0 7 SC Y 
CIS 7 23.4 F 2.5 8 SC N 
CIS 8 48.5 M 1.0 3 BS N 
CIS 9 49.3 F 1.0 3 BS Y 
CIS 10 41.5 F 1.0 2 BS Y 
CIS 11 36.1 M 2.5 4 SC Y 
CIS 12 34.2 F 4.0 6 BS Y 
CIS 13 29.6 F 0.0 4 SC Y 
CIS 14 31.3 F 1.5 4 SC Y 
CIS 15 37.4 F 1.5 10 SC Y 
CIS 16 38.3 F 2.0 8 SC Y 
CIS 17 34.9 F 2.0 1 SC withdrawn* 
CIS 18 47.4 M 1.5 5 BS Y 
Mean (SD) 38.5 (7.8) 12 F; 6 M 1.7 (1.0) 5.3 (2.6)  4N; 12Y 
Table 5.1. Clinically Isolated Syndromes population demographic and clinical characteristics, in 
order of PET scan date (from oldest to newest). EDSS=Expanded Disability Status Scale; ON=optic 
neuritis; BS=brainstem; SC=spinal cord; HP=haemispheric; F=Female; M=male; Y=yes; N=no. *Two 
patients withdrew, they didnt have any relapses and felt well at 2 years. 
MRI characteristics of population 
The eight HC subjects MRI was explored for possible occasional unspecific lesions, which 
resulted negative. CIS patients MRI lesion number and volume is reported in Table 5.2. 
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T2 lesion load 
Median volume (cm
3
) 
Range/p 
T2 lesion number 
Median  
Range/p 
T1 Gd+ lesion number 
Median  
Range/p 
Baseline (18 subjects) 
1.19 
0-19.64 
7 
0-68 
0 
0-15 
Baseline of CIS who 
completed the FU 
(16 subjects) 
1.76 
0-19.64 
9.5 
0-68 
0 
0-15 
2 Year FU 
(16 subjects) 
3.47 
0-16.31 
15.5 
0-84 
0.5 
0-7 
Baseline MRI 
CIS (4 subjects) vs MS 
(12 subjects) 
0 vs 2.87 
p=0.004 
0 vs 13.50 
p=0.003 
0 vs 0 
p=0.444 
2 Year FU MRI change 
CIS (4 subjects) vs MS 
(12 subjects) 
0 vs 1.35 
p=0.098 
0 vs 5.50  
p=0.016 
0 vs 0.50 
p=0.218 
Table 5.2. CIS MRI data at baseline and 2years follow-up. CIS: clinically isolated syndromes; FU: 
follow-up; SD: standard deviation MRI: magnetic resonance imaging; Gd+: gadolinium enhancing. 
Among the sixteen patients who completed the FU, 13 satisfied the radiological criteria of 
DIS and 13 the DIT at 2 years. The T2 lesion load was higher in patients who converted to 
MS vs non-converter both at baseline and at the 2-year FU, respectively 0 vs 2.87cm
3
 
(p=0.004) and 0 vs 1.35cm
3
 (p=0.098), as well as the lesion number, respectively 0 vs 13.50 
(p=0.003) and 0 vs 5.50 (p=0.016). Finally, the T2 MRI lesions had significantly higher 
PKBPND than NAWM, respectively 0.153 (±0.095) and 0.071 (±0.031), p=0.0051 (Fig.5.1). 
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Figure 5.1. PK binding in lesions and normal appearing white matter (NAWM) of CIS patients. 
The average of PKBPND for each subject in NAWM and WM lesions. The BPND (Y-axis) average in 
NAWM is 0.071, whereas in WM lesions it is 0.153. Horizontal bars represent mean and standard 
error of mean. 
PK-PET global changes in CIS NAWM 
I first considered the difference between the two groups (HC and CIS) according to the 
subjects PKBPND average in NAWM. In CIS subjects this resulted significantly higher than 
in controls, respectively 0.071 vs 0.042 p=0.024, Fig.5.2a. Since in each subject the PK was 
measured in multiple ROIs, the distribution of all the regions for each group was considered 
and compared. In NAWM the PKBPND distribution across all the ROIs of CIS patients was 
significantly different compared with the one of HC subjects, p<0.0001, Fig.5.2b. In order to 
test the possibility of one or more regions influence on the difference found using subjects 
average, I performed the GLM for repeated measures with ROIs as the repeated factor and 
Group as a between-subject factor. The test showed a significant Group effect (p=0.014, Fig. 
5.2c), implying a significant difference of PKBPND in NAWM between CIS and HC, and no 
significant difference in the ROIs effect (p=0.414), consistent with a diffuse global change in 
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the CIS group NAWM, independent on the specific ROIs. There was no significant 
difference when the type of clinical symptom was considered. 
 
Figure 5.2. Global changes in normal-appearing white matter (NAWM) in subjects with CIS 
compared with healthy controls (HC). (A) The average of PKBPND (Y-axis) for each subject 
represented by a black dot (HC PKBPND average in NAWM is 0.042, whereas it is 0.071 in CIS 
subjects). Horizontal bars represent mean and standard error of mean. (B) Significant difference in 
NAWM regions frequency distribution (Y-axis, percentage) according to their PKBPND (X-axis) 
between HC and CIS. This inset shows a higher percentage of NAWM regions with low PKBPND in 
HC (left) than CIS (right). (C) Significant group effect studied using repeated measures with NAWM 
regions of interest as the repeated factor and group (left, HC right CIS) as a between subject factor. 
Horizontal bars represent mean and standard error of mean. 
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Presence of T2 MRI lesions in CIS and PKBPND in NAWM 
Since the major predictor of MS conversion in CIS population is represented by the presence 
of WM lesions at T2 MRI, I tested the difference of NAWM PKBPND between the group of 
CIS patients without lesions and the group of subjects with WM lesions. The average per 
subject was significantly different between the two groups, being the PKBPND for CIS with 
and without lesions respectively 0.078 and 0.032, p=0.017 Fig.5.3a. Then I tested whether 
this difference was driven by one or more ROIs with repeated measure, using Group as 
between factor and ROIs as within factor. Again, the results showed a significant group effect 
(p=0.009, Fig.5.3b) and a non-significant ROI effect. The increased PKBPND of CIS with 
lesions compared with CIS without, is therefore globally diffused in NAWM. The importance 
of the WM damage seen at T2 MRI in CIS subjects is also confirmed by the significant 
correlation between PKBPND in NAWM of patients with lesions and their clinical disability at 
EDSS, p=0.007, Fig. 5.3c. 
 
Figure 5.3. Global changes in normal-appearing white matter (NAWM) in CIS subjects without 
T2 white matter (WM) lesions at MRI scan compared with CIS subjects with T2 WM lesions. 
(A) The average of PKBPND (Y-axis) for each subject represented by a black dot (CIS without WM 
lesions PKBPND average in NAWM is 0.032, whereas it is 0.078 in CIS subjects with WM lesions). 
Horizontal bars represent mean and standard error of mean. (B) The significant group effect studied 
using repeated measures with NAWM regions of interest as the repeated factor and group (left, CIS 
without WM lesions; right, CIS with WM lesions) as a between subject factor. Inset C shows the 
significant correlation between PKBPND (Y-axis) and EDSS (X-axis) in CIS with WM lesions (r = 
0.673); dotted lines represent error bars. 
NAWM PK-PET in CIS population at 2-year FU 
Performing the same analysis on the population that completed the FU according to the 
conversion to MS at 2 years, the group which converted showed higher PKBPND at baseline 
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in NAWM. The PKBPND average in MS-converted and subjects remained CIS at 2 years was 
respectively 0.080 vs 0.045 (the latter very close to the controls PKBPND, 0.042), p=0.040, 
Fig.5.4a. Despite this significant result, it cant be considered an independent predictor of MS 
development, especially considering the association between increased PK binding in the 
NAWM and the presence of WM lesions at MRI. This significant difference was found to be 
driven by subjects who fulfilled the criteria for DIS, for whom the increase was more 
significant (p=0.014), rather than subjects who didnt (p=0.207), Fig.5.4b. Performing the 
repeated measures, as described above, I found again a significant Group effect (p=0.048), 
with no ROI effect (p=0.612) when considering subjects converted to MS vs patients 
remained CIS, Fig.5.4c. When the groups were performed according to the DIS criteria 
satisfaction, the repeated measures showed a significant Group effect (p=0.007) and a non-
significant ROI effect (p=0.369), Fig.5.4d. The baseline PK-PET showed therefore a 
significant different global NAWM PKBPND in patients who, at 2 years, converted to MS, 
which was even more significant in patients who satisfied the DIS criteria, but not DIT. 
 
Figure 5.4. Baseline PKBPND in normal-appearing white matter (NAWM) of healthy controls 
(HC) and CIS according to their dissemination in space (DIS) and MS diagnosis at the 2-year 
follow-up (FU). (A) The average of PKBPND (Y-axis) for each subject is represented by a black dot. 
On the X-axis respectively HC, CIS who didnt and did develop multiple sclerosis at 2-year FU; 
horizontal bars represent mean and standard error of mean; (B) The average of PKBPND (Y-axis) and 
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on the X-axis respectively CIS with or without DIS at 2-year FU. (C) The significant group effect 
studied using repeated measures with NAWM regions of interest as the repeated factor and Group as a 
between subject factor (left, CIS who didnt develop multiple and right, CIS who developed multiple 
sclerosis at 2-year FU); (D) left, CIS without DIS and right, with DIS at 2-year FU. 
2. Extending the NAWM PK-PET study from CIS to MS 
The clinical and demographic characteristics of MS subjects are shown in Table 5.3. The 
nineteen MS subjects age, age at onset and EDSS score had respectively a mean (±SD) of 
38.8 (±9.5), 25.2 (±7.4) years and 6.2 (±1.7). Seventeen were females, 11 with RR and 8 with 
SP course. Fourteen were not under treatment at the time of the enrolment, 2 were treated 
with GA, 2 with interferon beta and one with cyclophosphamide. They were enrolled, 
examined and underwent MRI and PET scans in 13.7 (±9.2) years from the clinical onset. 
Figure 5.5 shows PK-PET images of the population extended to MS. 
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Subject Age 
Age at 
onset 
Disease 
duration 
EDSS Course Medication
a
 
MS 1 29.5 25.8 3.6 9.5 Progressive Cyclophosphamide 
MS 2 31.6 18.6 13.0 4.0 Relapsing None 
MS 3 46.3 21.2 25.1 8.5 Progressive None 
MS 4 26.1 18.4 7.7 7.0 Progressive Copaxone 
MS 5 42.0 13.9 28.2 7.0 Progressive None 
MS 6 33.1 26.1 7.1 8.0 Relapsing Interferon β-1a 
MS 7 47.6 34.4 13.2 4.0 Relapsing None 
MS 8 28.9 25.2 3.8 7.0 Progressive None 
MS 9 43.5 20.4 23.1 5.5 Progressive None 
MS 10 57.8 46.5 11.3 6.5 Progressive None 
MS 11 39.1 25.7 13.4 6.5 Relapsing None 
MS 12 49.4 20.0 29.4 8.0 Progressive None 
MS 13 25.2 21.8 3.4 4.5 Relapsing None 
MS 14 47.1 27.9 19.2 6.5 Relapsing Copaxone 
MS 15 46.6 35.0 11.6 6.0 Relapsing None 
MS 16 43.7 19.0 24.6 3.5 Relapsing None 
MS 17 42.3 23.3 19.0 4.0 Relapsing None 
MS 18 31.3 28.9 2.4 6.5 Relapsing None 
MS 19 26.8 25.9 1.0 5.5 Relapsing Interferon β-1a 
Mean (SD) 38.8 (9.5) 25.2 (7.4) 
13.7 
(9.2) 
6.2 (1.7) 19 Total  
Mean (SD) 37.7 (8.4) 26.0 (5.4) 
11.6 
(7.6) 
5.4 (1.4) 11 Relapsing  
Mean (SD) 40.4 (11.2) 23.9 (9.9) 
16.5 
(11.0) 
7.4 (1.2) 8 Progressive  
R-P mean 
difference 
ns ns ns *   
Table 5.3. MS population demographic and clinical characteristics. Subjects in order of PET scan 
date (from oldest to newest). EDSS: Expanded Disability Status Scale; R-P: Relapsing-Progressive; 
a
: 
medication for MS at the PET scan; SD: Standard Deviation; ns: non-significant; * p=0.006. 
 
77 
 
 
Figure 5.5. Normal appearing white matter (NAWM) on PK-PET images co-registered and 
fused with MRI of five subjects of the study population. The first subject is a healthy control (A) 
with PKBPND in NAWM of 0.028; the second is a CIS subject without T2 MRI lesions (B), an EDSS 
score of 3.5 and PKBPND in NAWM of 0.037; the third is a CIS subject with T2 MRI lesions (C), 
EDSS = 2.0 and PKBPND in NAWM of 0.136. The fourth is a relapsing-remitting patient (D), EDSS = 
6.0 and PKBPND in NAWM of 0.143; the fifth is a secondary progressive MS patient (E), EDSS = 9.5 
and PKBPND in NAWM of 0.314. The colour scale bar represents the PK BPND, L=low, H=high. 
PKBPND average in NAWM across subjects disease course. 
In testing the difference between the four groups considered (HC, CIS, RR and SP) I first 
checked their PKBPND average, which was significantly different (p=0.0134). Since this 
analysis showed a significant difference in subjects average across the four populations, I 
then tested the difference between each group against each other, six comparisons corrected 
for multiple testing. Performing this analysis, the only difference remaining significant after 
correction for multiple comparisons is HC vs SP, respectively 0.042 vs 0.130 (p<0.05). Given 
the results previously showed, where CIS non-converting and CIS without lesions appeared 
to have PKBPND in NAWM very close to controls, I here tested for significant difference 
between CIS (according to their conversion and presence of lesions) and RRMS patients. 
Among those, the only difference showing a trend (p=0.0549) was between CIS without 
lesions and RRMS. Figure 5.6 shows the average per subject according to the different 
populations. 
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Figure 5.6. Normal-appearing white matter (NAWM) PKBPND in the study population. On the 
Y-axis the PKBPND. On the X-axis, from left to right: healthy controls, CIS who didnt and did 
develop MS at the 2-year follow-up, relapsing remitting and secondary progressive subjects. 
Horizontal bars represent mean and standard error of mean. 
 
General distribution of the different populations according to the PKBPND in NAWM 
Testing the distribution of the several ROIs across the four groups, they were significantly 
different (p<0.0001, Fig.5.7). When considered as couples, the ones that remained 
significantly different after correction for multiple comparisons were HC vs CIS (p<0.001), 
CIS vs SP (p<0.01) and HC vs RR and HC vs SP (both p<0.0001). 
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Figure 5.7. Histogram representing the frequency distribution (in percentage) of the PKBPND of 
the region of interest sampled in the normal-appearing white matter (NAWM) for each course. 
Significant difference in NAWM regions frequency distribution (Y-axis, percentage) according to 
their PKBPND (X-axis) between healthy controls, CIS, relapsing and progressive subjects.  
Multiple regions distribution of the different populations according to the PKBPND in 
NAWM 
The GLM for repeated measures with ROIs as the repeated factor and Group as a between-
subject factor was applied to investigate the possible influence of specific ROIs to the 
difference found between groups, Fig. 5.8. Significant difference in the between groups were 
found considering the three groups HC, CIS and MS (p=0.003, Fig. 5.8a), four groups HC, 
CIS, RR and SP (p=0.002, Fig. 5.8b) but also splitting CIS either in with or without lesions 
(p=0.002, Fig. 5.8c) and according to their FU, non- vs converted at 2 years (p=0.004, Fig. 
5.8d). None of these had significant values at the test within groups, implying that there was 
no significant ROI effect and the increase of PKBPND in NAWM was globally increased and 
uniform across the ROIs. 
80 
 
 
Figure 5.8. Between-subjects changes in normal-appearing white matter (NAWM) according to 
the subgroups. (A) Group effect studied using repeated measures with NAWM regions of interest as 
the repeated factor and Group (from left to right, healthy controls (HC), CIS and MS) as a between 
subject factor; (B) groups from left to right: HC, CIS, relapsing-remitting (RR) and secondary 
progressive (SP) MS subjects; (C) groups from left to right: HC, CIS without WM lesions, CIS with 
WM lesions, RR and SP subjects; (D) groups from left to right: HC, CIS who didnt develop MS, CIS 
who developed MS at the 2-year follow-up, RRMS and SPMS subjects. 
Clinical scores and NAWM PK-PET across all the groups 
Analysing the PKBPND in NAWM and clinical scores across all the groups considered, the 
average of the NAWM values in subjects was used, since the analysis for repeated measures 
previously performed didnt show any significant difference in the within test, suggesting that 
there was no influence of any specific ROI. Looking at the EDSS across the courses, its 
scores increase paralleling the increase of the PK binding, Fig. 5.9. Exploring the possibility 
of a correlation between EDSS scores and PK binding in the whole population, this results to 
be significant (p=0.007; r=0.4356). The correlation between PK binding and MSIS-29 scores 
was not significant. 
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Figure 5.9. Increased PKBPND within the courses parallels increased disability. This graph shows 
two variables, PKBPND and EDSS score, in the CIS, relapsing remitting and secondary progressive 
groups. The X-axis shows the disease courses; on the left Y-axis is represented the PKBPND; the right 
Y-axis shows the EDSS score. The dots represents average and the bars the standard deviation. 
Clinical correlate of PK binding in progressive patients NAWM 
Having identified subgroups for relapsing and progressive patients according to their 
outcome, as reported and described in CHAPTER 4, Table 4.3, I retrospectively analysed 
their PK-PET scans. The PK binding in RR subjects NAWM didnt differ between the two 
subgroups, while for progressive subjects there was a significant difference according to their 
outcome (Fig. 5.10). Progressive patients with worse outcome at 2 years had significantly 
higher PK binding than subjects with better prognosis, respective average 0.188 and 0.072 
(p=0.029). 
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Figure 5.10. PKBPND in progressive patients according to their outcome. The average of PKBPND 
(Y-axis) for each progressive subjects represented by a black dot. Patients with better outcome at 2 
years had a baseline PKBPND average in normal-appearing white matter of 0.072, whereas it is 0.188 
in subjects with worse outcome. Horizontal bars represent mean and standard error of mean. 
Discussion 
The analysis of PK binding in NAWM shows a globally increased microglia activation across 
the subgroups of my population. In CIS subjects the PK binding is increased compared with 
the HC both considering the average per subjects and the ROIs, with uniform characteristic. 
This is true also for the increase of PK binding in CIS patients with lesions compared with 
those without, the former having also their disability correlating with the PK binding. Again, 
for patients who developed MS at the 2 years FU, compared with those who remained CIS, 
the increased PK binding is significant in the average per subjects and globally throughout 
the ROIs. Extending the analysis to the MS course, the PK binding is further increased in RR 
and even further in SP patients. Interestingly, dividing CIS subjects according to the presence 
of WM lesions and their outcome at 2 years, the subjects without lesions and who didnt 
convert to MS have PK binding values very close to the HC ones and the CIS patients with 
lesions and who converted to MS at the FU show PK binding values very close to the RR 
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subjects. Also for the MS subgroups the PKBPND increase is uniform across ROIs. The 
NAWM PK binding is also higher in MS patients with worse clinical outcome at 2 years, 
only in the progressive course. 
The study of NAWM with PK-PET imaging was thus shown to be a useful tool across the 
different courses of MS, paralleling the evolution of the disease with the associated disability 
and having possible prognostic values since the very early stages of MS. 
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CHAPTER 6: Microglia activation in grey matter 
Background 
Despite the involvement of the GM in MS has been known since the 19
th
 century (Charcot, 
M., 1868), the scientific community only recently has recognized that it may have a 
fundamental importance in the course of MS. Typical features in the MS cortical GM 
pathology include lower degree of inflammation and adaptive immune cells infiltrates, 
associated with efficient myelin repair and less gliosis than in the WM lesions (Albert et al., 
2007; Reynolds et al., 2011). One of the reasons for the underestimation occurred until recent 
time, could reside in the low sensitivity of MRI with respect to the cortical changes. The 
development of new MRI methodologies has brought a renewed scientific interest regarding 
GM lesions in MS. These methodologies include double inversion recovery, spoiled gradient-
recalled echo, phase-sensitive inversion recovery, MRS, high field MRI, MTR and DTI. 
From these new MRI techniques, a reduction of NAA at MRS and atrophy in thalamus of MS 
subject with consistent neuronal loss at the immunohistopathological staining were reported 
(Calabrese et al., 2010a; Cifelli et al., 2002; Schmierer et al., 2010). Furthermore, rather than 
the WM, the GM damage in MS is referred as a better correlate to disability and its 
progression (Calabrese et al., 2010b; Cifelli et al., 2002; Geurts and Barkhof, 2008; 
Magliozzi et al., 2007, 2010; Schmierer et al., 2010). In CIS subjects several MRI recent 
studies reported evidences of regional atrophy: the superior frontal gyrus, thalamus, and 
cerebellum atrophy were reported as independent predictors of conversion to MS (Calabrese et 
al., 2011); in another study a decrease in GM fractional volume was found to be predictive of 
MS development within 3-year time FU, in absence of significant decrease in WM volume 
(Dalton et al., 2004). 
Microglia is known to become activated even before the onset of symptoms, being one of the 
first cell populations present on the site of the forthcoming histological alteration and playing 
a fundamental role to its beginning (Banati et al., 1997; Chen et al., 2004; Kuhlmann and 
Guilarte, 2000).  Knowing the early occurrence of GM atrophy in CIS subjects, it is 
interesting to explore their levels of activated microglia in GM. Moreover, activated 
microglia was shown to highly contribute several features of GM damage strongly associated 
with clinical progression. In this contest, the close relationship between activated microglia in 
cortical lesions and the presence of meningeal inflammation with follicles, described in 
SPMS patients with poor clinical history (Magliozzi et al., 2007) contributes to the interest in 
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studying the microglia activation in the cortex of MS subjects, and more generally GM, 
exploring the possible association with patients disability. 
It is therefore aim of this study to assess the in vivo patterns and extent of the GM microglia 
activation with PK-PET in my population, both studying their contribution at the earliest 
stages of the disease and exploring their prognostic value and possible association with 
clinical progression in later MS stages. 
Specific methods 
Statistical analyses 
Statistical analysis has been carried out as for CHAPTER 5. 
Results 
1. Analysis of the GM in CIS population 
Clinical and MRI characteristics of CIS population 
The population used for the analysis of GM is the same used for the analysis of the NAWM, 
CHAPTER 5 (Tab.5.1 for CIS, Tab. 3.1 for HC subjects). 
PK-PET changes in CIS total GM 
Exploring the difference in subjects average PKBPND in total GM in HC and CIS there was 
no statistical difference between the two populations, respectively 0.098 (±0.026) and 0.071 
(±0.022) p=0.257. Similar results were obtained studying the distribution of all the ROIs 
PKBPND and the GLM analysis, which didnt show any significant difference between HC 
and CIS, respectively p=0.083 and p=0.365. 
Analysing the difference of the total GM PKBPND according to the presence of T2 MRI 
lesions or the MS conversion at 2 years, I didnt find any significant result. 
The analysis performed using EDSS and MSIS-29 scores as clinical correlates, didnt show 
any significant result. 
PK-PET changes in CIS cortical GM 
Analysing the difference in subjects average PKBPND in cortical GM in HC and CIS there 
was no statistical difference between the two populations, respectively 0.082 (±0.025) and 
0.084 (±0.021) p=0.158. As for the average per subject, the distribution of all the ROIs 
PKBPND and the GLM analysis were not significantly different between HC and CIS, 
showing the first only a trend, respectively p=0.056 and p=0.335. 
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Analysing the difference of the cortical GM PKBPND according to the presence of T2 MRI 
lesions or the MS conversion at 2 years, I didnt find any significant result. 
The analysis performed using EDSS and MSIS scores as clinical correlates, didnt show any 
significant result. 
PK-PET changes in CIS central GM structures  
Unlike the other GM analysis previously performed, the central structures (CS) showed a 
significant difference between HC and CIS in the PKBPND average per subject (Fig. 6.1), 
respectively 0.167 (±0.015) and 0.197 (±0.036) p=0.006 (Fig.6.2a). The repeated measures 
for the CS ROIs showed a significant group effect (p=0.028, Fig.6.2b), with no ROI effect 
(p=0.136) or statistical difference in the ROIs distribution between HC and CIS (p=0.269). 
 
Figure 6.1. PK-PET in healthy control (HC) and CIS grey matter (GM). Co-registered images of 
MRI and PK-PET of two different subjects. The images on the top (A, B) are coronal T1 MRI section 
and the ones at the bottom (C, D) the correspondent PK-PET images showing only the GM. The first 
subject is a HC (images on the left, A and C) with PKBPND in total GM of 0.079; the second is a 
subject with CIS (B), EDSS = 4.0 and PKBPND in total GM of 0.167. The colour scale bar represents 
the PKBPND, L=low on the left to H=high on the right. 
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Analysing the difference of the PKBPND in CS according to the presence of T2 MRI lesions, 
the group with lesions had higher PKBPND than the group without, respectively 0.208 
(±0.059) and 0.153 (±0.051) with a significant group effect (p=0.049, Fig.6.2c) with no ROI 
effect (p=0.635) or different distribution (p=0.281). The CIS group that converted to MS at 2 
years didnt have any significant PKBPND increase in CS. 
The analysis performed using EDSS and MSIS-29 scores as clinical correlates didnt show 
any significant result, with the exception of a correlation between the PKBPND in CS at 
baseline and the MSIS-29 change at 2-year FU (r=0.597; p=0.015, Fig. 6.2d).  
 
 
Figure 6.2. PKBPND in central structures (CS) of healthy controls (HC) and CIS subjects. (A) 
The baseline average of PKBPND (Y-axis) in CS of HC and CIS subjects. Each data point represents 
the average of PKBPND for each subject; horizontal bars represent mean and standard error of mean; 
(B) significant group effect in CS PKBPND between controls and CIS and (C) between CIS without 
and with white matter lesions; (D) correlation between the MS impact scale -29 score change at the 2-
year FU (X-axis) and the baseline PKBPND in CIS CS (Y-axis). 
2. Extending the NAWM PK-PET study from CIS to MS 
The clinical and demographic characteristics of MS subjects are shown in table 5.3 and 
detailed in the CHAPTER 5. 
PKBPND average in GM across subjects disease course. 
In testing the difference between the four groups considered (HC, CIS, RR and SP) I first 
checked their PKBPND average per subject, which was not significantly different. This was 
true for the GM considered as a whole, p=0.416 (Fig. 6.3a), and for each structure separately, 
respectively cortical GM p=0.178 (Fig. 6.3b), insula and cingulate p=0.460 (Fig. 6.3c), CS 
p=0.252 (Fig. 6.3d) and posterior fossa p=0.523 (Fig. 6.3e). 
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Figure 6.3. PKBPND in different grey matter (GM) regions according to the course. On the Y-axis 
the PKBPND. On the X-axis the healthy controls, CIS, relapsing remitting and secondary progressive 
courses (from left to right) are represented in all the insets. Baseline PKBPND in (A) total GM, (B) 
cortical GM, (C) insula and cingulate, (D) central structures and (E) posterior fossa. Each data point 
represents the average of PKBPND for each subject. Horizontal bars represent means. 
General distribution of the different populations according to the PKBPND in GM 
Testing the distribution of the several ROIs across the four groups, they were significantly 
different (p<0.0001, Fig. 6.4). When considered coupled, only CIS vs RR (p<0.01) and CIS 
vs SP (p<0.001) remained significantly different after correction for multiple comparisons. 
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Figure 6.4. Histogram representing the frequency distribution (in percentage) of the PKBPND of 
the grey matter (GM) region of interest for each course. Significant difference in GM regions 
frequency distribution (Y-axis, percentage) according to their PKBPND (X-axis) between healthy 
controls, CIS, relapsing and progressive subjects.  
Different PKBPND distribution across the GM regions in the study population 
The GLM for repeated measures with ROIs as the repeated factor and Group as a between-
subject factor was then applied to investigate the possible influence of specific ROIs to the 
difference found between groups. Significant difference in the between groups were found, 
analysing the total GM, between CIS and SP course (p=0.046; with ROIs effect p=0.000006, 
Fig.6.5a), in CS between HC and RR (p=0.016; with ROIs effect p=0.047, Fig.6.5b) and in 
posterior fossa considering all the groups (p=0.000037; with ROIs effect p=1.124*E-9), 
whereas the difference in cortical GM showed only a trend of significance between CIS and 
SP (p=0.057). Considering that the results with a significant difference between groups also 
showed significant ROIs effect, differences between ROIs across groups of population were 
analysed and corrected for multiple comparisons. The ROIs pertaining to total GM tested 
between the CIS and SP course, remained significant after correction for multiple 
comparisons were the lateral occipito-temporal gyrus (p=0.0003) and the brainstem 
(p=0.00003). Since these two ROIs were shown to be significantly increased in SP patients, I 
explored the possibility of a clinical correlate, which was significant between EDSS and 
brainstem (r=0.766; p=0.027, Fig. 6.5c). Within the CS, between the HC and RR groups, only 
the thalamus and pallidum survived after multiple comparisons and none of them showed a 
90 
 
significant clinical correlate. Within the posterior fossa among all the groups, both the 
cerebellum (p=0.038) and brainstem (already mentioned) were significantly different. The 
cerebellum didnt show any significant clinical correlate. 
 
 
 
Figure 6.5. Significant differences between grey matter (GM) regions of interest (ROIs) across 
the courses. (A) Significant group effect in total GM PKBPND between CIS and secondary 
progressive (SP) patients; (B) group effect in central structures PKBPND between HC and RR subjects; 
(C) positive correlation between PKBPND (X-axis) in the brainstem of SP patients and their disability 
at EDSS score (Y-axis), each point represents the average of PKBPND for each subject. 
 
Having identified subgroups for relapsing and progressive patients according to their 
outcome, as reported and described in CHAPTER 4, Table 4.3, and performed in CHAPTER 
5 for NAWM, I retrospectively analysed their PK-PET scans. The PK binding in total GM of 
the two RR subjects subgroups didnt differ, while for progressive subjects there was a 
difference according to their outcome, at borderline of significance (p=0.057), the average for 
worse vs better outcome was respectively 0.172 vs 0.077. In view of the uneven distribution 
of PK binding in different GM structures, I repeated the analysis considering cortical GM, 
posterior fossa and insula and cingulate separately. Progressive patients with worse outcome 
at 2 years had significantly higher PK binding than subjects with better prognosis, respective 
average 0.170 and 0.065 in cortical GM (Fig. 6.6) and respectively average 0.292 and 0.159 
in CS, p=0.029. The same analysis on the RR didnt show any significant difference between 
the two subgroups. 
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Figure 6.6. Cortical grey matter (GM) PKBPND in progressive patients according to their 
outcome. The average of cortical GM PKBPND for each progressive subject is represented by a black 
dot. Patients with better outcome at 2 years had a baseline PKBPND (Y-axis) average in cortical GM of 
0.072, whereas it is 0.188 in subjects with worse outcome. Horizontal bars represent mean and 
standard error of mean. 
Discussion 
Contrary to the study of the NAWM, the GM didnt show a globally increased PK binding 
between HC and CIS, or across the MS courses. With regards to the analysis between CIS 
and HC, the cortical GM didnt show any significant difference, while the central GM 
structures had a higher PK binding in CIS subjects both considering the average per subject 
than the ROIs. This increase was uniform and also present between CIS with WM lesions 
compared with those without. Extending this analysis to the MS subgroups, although the 
average per patient was not significantly different across them, I found a difference in their 
ROIs distribution across the groups. This was also shown using the GLM, where the 
difference between groups had a very significant ROI effect, indicating a non-uniform 
change. One example of this is represented by the correlation between brainstem PK binding 
and disability in the progressive patients. The cortex and CS PK binding were also higher in 
MS patients with worse clinical outcome at 2 years, only in the progressive course. 
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In analysing the PK-PET imaging of GM throughout the several MS courses, I found the PK 
values not to be uniform, with regard to the different ROIs but also considering the disease 
evolution. The finding of two GM structures, cortex and CS, as predictive of worse clinical 
outcome in progressive patients only, makes the use of PK-PET important in those regions 
and helps in defining the role of activated microglia in the disease progression. 
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CHAPTER 7: Case report 
PK-PET enhancement without MRI changes prior to a clinical multiple sclerosis 
relapse: in vivo evidence for early innate immunity activation within the CNS in 
the absence of blood brain barrier breakdown 
Background 
Activated microglia has been reported in several inflammatory conditions involving the CNS, 
as well as in neurodegeneration. Their presence was shown in facial nucleus four days after 
facial nerve axotomy, which maintained the BBB intact and excluded the contribute of 
peripheral blood macrophages (Banati et al., 1997). In both EAE and MS, activated microglia 
was shown to be highly and early represented in typical demyelinated lesions (Barnett and 
Prineas, 2004; Nessler et al., 2007). The co-localisation between activated microglia and PK, 
was studied by double immunostaining for activated microglial markers to demonstrate the 
specific expression of TSPO by activated microglia (Banati et al., 1997, 2000; Benavides et 
al., 1991; Chen et al., 2004; Kuhlmann and Guilarte, 2000; Sauvageau et al., 2002; 
Stephenson et al., 1995; Venneti et al., 2008, 2009; Vowinckel et al., 1997). The presence of 
activated and proliferating microglia preceding the onset of CNS autoimmunity was 
demonstrated on EAE (Ponomarev et al., 2005); activated microglia represented the main 
inflammatory cell population before the symptoms onset and the peripheral macrophages 
lesion infiltration. 
Case 
The subject was 47 years old, female, with a 13 years history of MS. She reported a relapse 
rate of about 2 per year during the first 10 years of MS and 3 per year during the 3 years 
before I saw her. Before the enrolment to my study, she was due to start natalizumab 
according to the UK NICE criteria. During the previous 12 months her MRI showed new T2 
lesions accumulation, some of which subcortical. Her EDSS was 4.0 on the day of the PET 
scan. She was not on DMT but about to start natalizumab infusions. There was no 
concomitant treatment. In the past she was treated with IFNβ1a for 18 months, terminated 6 
months beforehand. The subject came to my observation because of a scheduled visit within 
the PK-PET study. On that day her medical history was updated and a neurological 
examination for the EDSS scoring was performed. The patient underwent the PK-PET scan 
on the same day. The PK-PET and MRI methodology was carried out as for methods 
described in the dedicated chapter. 
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The subject experienced an MS relapse two days after the PET scan, characterised by 
diplopia. Two days after the symptoms onset she had a MRI scan, which included the 
following sequences: T2, FLAIR and T1, the latter before and after the administration of Gd. 
After the MRI scan she was started on IV infusion of MP 1g for 3 days with complete 
recovery of the symptoms. Analysing the PK-PET scan, I found two areas of high PK 
enhancement in the pons (Fig. 7.1), consistent with the symptoms and with those already 
reported in MS active lesions (Debruyne et al., 2003). The mean PKBPND of those two areas 
were 0.727 and 0.608, representing respectively 2.9 and 2.4-fold the mean of the rest of the 
brainstem, 0.251. The MRI scan performed two days after the symptoms onset didnt show 
any correspondent Gd-enhancing lesion, nor hyperintensities at T2 sequences. 
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Figure 7.1. Axial view of co-registered PK-PET and MRI scan of the patient. (A) PK-PET and 
T1-MRI fused showing two regions of high PK uptake in the brainstem. The colour scale bar 
represents the PKBPND, L=low, H=high. (B) T1-MRI with gadolinium showing the absence of 
enhancement in brainstem.  
Discussion 
Here I show in vivo, for the first time in an MS patient, that microglia activation precedes the 
clinical onset of a relapse in absence of MRI detectable BBB breakdown, highlighting and 
confirming the fundamental importance of microglia activation at the earliest stages of MS 
lesion pathogenesis. 
This report demonstrates in vivo in human what already reported in animals: microglial 
activation, source of increased PK signal, precedes the symptoms onset and the BBB 
breakdown, being the first cell population becoming activated (Banati et al., 1997; 
Ponomarev et al., 2005).
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CHAPTER 8: Discussion 
 
In this study I used an indirect tool, PK-PET imaging, to investigate the activation of 
microglia in the brain of subjects affected by MS and CIS, in comparison with HC. 
PK has been used for long time as a PET tracer because of its favourable dynamics and 
kinetics. It is a non-benzodiazepine selective and high affinity TSPO ligand, with the ability 
to cross the BBB (Schweitzer et al., 2010). PK is also considered a rewarded option 
compared with other new tracers for TSPO such as [
11
C]DAA1106 (Probst et al., 2007) and 
[
11
C]PBR28 (Brown et al., 2007), which have higher affinity but are subject to other 
limitations. One example is the presence of different binding affinity for the PBR28 due to 
the existence of polymorphisms of the gene for the TSPO (Owen et al., 2011) or a lesser 
defined kinetic. The latter implies the use of arterial line for quantitative assessment, which is 
laborious for researchers and invasive for patients, compared with the well-established 
methodology for PK quantification (Tomasi et al., 2008; Turkheimer et al., 2007; Yaqub et 
al., 2012). 
Several studies have been performed with the aim of confirming the activated microglial cell 
population as PK target in CNS. Most of these studies showed the activated microglia as the 
only cellular population expressing TSPO. Shah and coll. performed PK-PET in EAE rat 
models and identified the macrophage/activated microglia as PK binding site (Shah et al., 
1994) as well as Vowinckel in a mouse model of EAE (Vowinckel et al., 1997), Banati both 
in EAE and human post mortem MS tissue (Banati et al., 2000), and Venneti in post mortem 
tissue from various neurological diseases including MS (Venneti et al., 2008). However, there 
are a few reports, performed on cuprizone induced lesion (Chen et al., 2004) or ethanol-
induced lesions (Maeda et al., 2007), in which the TSPO expression was associated with a 
transient and minimal astroglial component, further to the more solid microglial one. Despite 
this incomplete consistency, the possible astroglial quote was reported to not influence the in 
vivo PK-PET imaging (Cagnin et al., 2002, 2007). In the appendix to this thesis the 
expression of TSPO by cell populations other than microglia/macrophages is discussed in 
more details. 
PK-PET, and in a wider view PET imaging using tracers binding the TSPO, have been used 
for other neurological conditions, as well as MS for at least 25 years. Regarding the studies 
performed on MS patients, the majority focused on T1 enhancing and T2 WM lesions,  
finding increased microglia activation in their ROIs (Banati et al., 2000; Colasanti et al., 
2014; Debruyne et al., 2003; Oh et al., 2011; Rissanen et al., 2014; Vas et al., 2008; 
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Vowinckel et al., 1997). Further to these regions, Debruyne reported a positive correlation 
between PK binding and disease duration (Debruyne et al., 2003); Versijpt showed a positive 
correlation between PK binding in NAWM and brain atrophy and a negative correlation 
between PK binding in T2 lesions and cerebral atrophy (Versijpt et al., 2005); Ratchford 
reported a reduction of global and regional PK binding after 1 year of GA treatment 
(Ratchford et al., 2012); Rissanen showed increased PK binding in NAWM and thalamus in 
SPMS patients (Rissanen et al., 2014). 
In my study, in which I aim to identify of further data supporting the role of activated 
microglia in MS, I decided to focus on regions that were of particular interest considering the 
evolution of this demyelinating disease, from CIS to progressive MS. These regions are 
represented by the GM, NAWM and BH and the reasons why they are of interest are 
discussed in the respective specific introductions and later in this discussion. 
During this study a subject reported an MS relapse two days after a PK-PET scan and 2 days 
before the MRI scan. This patients scans were analysed and the results provide further 
precious information on the role of activated microglia in MS. These latter results are 
discussed here first since they help in refining the chronological evolution of microglial 
activation in the disease. 
Microglia/macrophage activation precedes the onset of the clinical and 
radiological (MRI) manifestation of a relapse. 
As reported in the results, a patient having her scheduled PK-PET scan reported a relapse two 
days afterwards, the PK-PET showing two regions of uptake consistent with the clinical 
symptoms; the MRI performed two days after the clinical onset was lacking Gd-
enhancement. The microglial activation preceding the symptoms onset in a MS animal model 
was reported by Ponomarev and coll. With the aid of EAE induced in bone marrow chimera 
mice they differentiated between activated microglia and infiltrating macrophages 
(Ponomarev et al., 2005). Their results showed a subpopulation of microglia which became 
activated before the symptoms onset and the infiltration of macrophages from peripheral 
blood. Activated microglia proliferated in CNS and differentiated into DC and macrophages. 
These two CNS-derived cell populations at the pick of the disease represented the 40% of 
microglia.  
The contribution of innate immune cell populations, in particular DC and microglia, during 
the early stages of CNS autoimmunity has been usually referred to their role as APC. 
McMahon and coll. suggested the DC as antigen presenter to naïve T cells and microglia to 
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specific Th cells (McMahon et al., 2005). This implies that once primed, microglia are able to 
re-activate and work as APC. Hence, after the first contact with T cells, microglia can 
become activated and start a MS lesion/relapse. One further piece of evidence is reported by 
Katz-Levy and coll., who used the TMEV model to describe the antigen presentation capacity 
by microglia (Katz-Levy et al., 1999). Isolated from CNS infected mice with a pre-existing 
demyelination, microglia worked as APC, presenting myelin epitopes to specific Th1 cells in 
both the acute and chronic stage of the disease, increasing the epitope spreading. 
Interestingly, microglia extracted from naïve mice or during acute disease (without a pre-
existing demyelination) were not able to present antigens to Th1 cells. The presence of 
activated microglia in NAWM was reported by van Horssen to occur without evident BBB 
disruption, with presence in NAWM of microglia nodules in 67% of MS subjects, where 
there was no demyelination, T cell infiltration, axonal loss or astrocytes activation (van 
Horssen et al., 2012). These alterations were defined as preactive lesions.  
Fibrinogen as a possible trigger for microglia activation in CNS is reported by Adams, where 
fibrinogen was able to activate microglia (Adams et al., 2007). Leak of fibrinogen was 
associated with tight junction abnormalities, with decreasing prevalence in active, non-active 
lesions and NAWM of respectively 42, 23 and 13% (Kirk et al., 2003; Leech et al., 2007; 
McQuaid et al., 2009; Padden et al., 2007; Plumb et al., 2002). These data therefore provides 
one possible explanation for the onset of a clinical MS relapse due to microglia activation in 
absence of Gd-evident BBB breakdown. 
Of great interest is the report by Gay and coll. which groups pathologically MS lesions 
according with their age. The earliest lesions (Type I) are described as the primarily 
demyelinating plaque characterised by an in situ activation of resident microglia and close to 
normal total parenchymal cell counts (Gay et al., 1997). In these 13 very early MS cases, 
CD4 T cells were absent or very low in number in early plaques in contrast to the older ones. 
This allowed the authors to speculate that different inflammatory mechanisms underlie 
mature lesions, where the Type I plaques disappear. Another pathology study on 12 MS 
patients who died during or shortly after a relapse describes the formation of a new MS 
lesion, in which microglia represent the first cell population reaching the lesion (Barnett and 
Prineas, 2004). Marik and coll. reported the genesis of hypoxia-like MS lesions in which 
activated microglia expressing high level of i-NOS, was associated with sparse lymphocytic 
infiltrates restricted to the perivascular space (Marik et al., 2007); furthermore, fibrin deposits 
were mainly found attached to activated microglia in very early (pre-demyelinating) lesions, 
in a context of preconditioning proteins (Hsp70 and HIF-1α) up-regulation. Preconditioning 
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protein expression was absent in active demyelinating lesions, where the fibrin was no longer 
attached to activated microglia but dispersed diffusely throughout the tissue. The authors 
comment that activation of microglia alone, possibly by fibrin, is sufficient to induce this 
pattern of lesion. 
Interestingly, neurodegeneration is present from the beginning of the inflammatory phase in 
EAE, caused by microglia-secreted TNFα, occurring before the clinical onset of EAE 
(Centonze et al., 2009). Furthermore, inhibiting microglial activation at early stages of EAE 
can positively affect the clinical outcome (Bhasin et al., 2007; Heppner et al., 2005; Howell 
et al., 2010). 
The possibility of a detectable lesion at MRI FU in cases of PET enhancement was already 
described. Using [
11
C]PBR28-PET in MS subjects, Oh and coll. describe an increased 
binding in WM regions which only one month later showed a new MRI lesion (Oh et al., 
2011). In my report however, the MRI performed at 12 months FU didnt show any lesion in 
the corresponding place. This could be due to: (i) a poor ability of sequences performed 
(T2/FLAIR) in individuating lesions in the posterior fossa; (ii) the thicker slices performed in 
T2/FLAIR sequences (5mm) with respect to the T1 ones (1mm); and, (iii) the possibility of a 
transient lesion, explainable as a pattern III lesion with neuronal mitochondria block induced 
by microglia-secreted ROS (Mahad et al., 2008) and subsequently recovered. 
My finding is the first, in my knowledge, of increased microglia activation before the clinical 
symptoms of an MS relapse. This finding further (or definitively) confirms that in MS 
subjects microglia activation precedes both the onset of symptoms and MRI visible BBB 
breakdown and consequent T2 lesion. This microglia activation occurring before the relapse 
can be detected by PK-PET. 
Diffuse microglia activation in NAWM of subjects who have experienced the first 
episode of demyelination 
In this part of the study NAWM PK binding was shown to be globally increased in CIS 
compared with HC at baseline and interestingly this increase was driven by subjects with T2 
WM lesions. Consistent with the known increased risk of MS in patients with T2 WM 
lesions, I found a higher NAWM PK binding at baseline in those who developed MS at the 2 
years FU. 
The group of this part of the study is represented by 18 CIS subjects, 16 of them followed-up 
clinically and with MRI for 2 years. Their conversion rate to McDonald confirmed MS is 
high taking into consideration the number of subjects followed up for 2 years (12 converted 
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vs 4 who did not convert). However, the two CIS patients lost didnt come back to the FU 
visit because they felt well. Including them in the population would make it a typical CIS one 
(Chard et al., 2011). 
The exploration of microglia activation in NAWM of CIS patients is based on imaging 
(MRS) and pathology studies. The former showed a possible predictive role for changes in 
CIS NAWM (Wattjes et al., 2008) present even at the RIS stage (Stromillo et al., 2013); 
neuropathological studies, showed activated microglia in NAWM (De Groot et al., 2001) 
associated with axonal loss independent of demyelination (Bjartmar et al., 2001; Howell et 
al., 2010) and lymphocytic infiltration (Howell et al., 2010). The presence of activated 
microglial clusters (van Horssen et al., 2012), was reported in preactive lesions  NAWM  
without evidence of BBB disruption. 
The finding of a globally increased microglial activation in NAWM of CIS subjects, would 
be therefore consistent with the reported presence in NAWM of underlying areas possibly 
predisposed to lesion formation, characterised by clusters of activated microglia (van Horssen 
et al., 2012) and associated with diffuse axo-glial disruption (Howell et al., 2010) affecting 
nodes of Ranvier. The increase is particularly evident in CIS patients who displayed MRI T2 
lesions at baseline, which is consistent with the well-known higher risk of this group in 
developing MS compared with those without MRI T2 lesions (Chard et al., 2011; Fisniku et 
al., 2008). Alongside the presence of WM lesions, higher PK binding in NAWM was 
associated with a higher risk of developing MS at 2 years - predominantly through 
subsequent DIS. This association between the high PK binding in NAWM at baseline and the 
higher rate of DIS criteria fulfilled is suggestive, from a pathological view, of the 
predisposition of NAWM with high microglial activation in developing new WM lesions. 
Considering that the presence of microglial activation in NAWM is not associated with 
demyelination but with axonal loss (Bjartmar et al., 2001; Howell et al., 2010) and axo-glial 
disruption, including nodes of Ranvier pathology (Howell et al., 2010), it is likely that in my 
population the high NAWM PK binding in subjects with WM lesions has a toxic, rather than 
protective effect on axons. This is supported by the result of the PK binding correlation with 
the EDSS seen in subjects with MRI T2 WM lesions. Higher PKBPND is probably associated 
with axonal damage that is unlikely to be transient, since those patients with higher PK 
binding in NAWM are also those with higher risk of developing MS at 2 years. However, due 
to the limited population of this study, the interpretation provided represents only one 
possible explanation. 
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In MS with progression there is a further increase in global NAWM microglia 
activation 
My results on the microglia activation in the NAWM across the MS courses show a 
progressive and global increase from the CIS to the progressive stage. This is in keeping with 
most of the pathological studies (Kutzelnigg et al., 2005; Reynolds et al., 2011), some of 
which even showed a correlation between the extent of activated microglia and neuronal loss 
(Kuhlmann et al., 2002). The first level of PKBPND increase seems to be dependent on the 
presence of WM lesions, indeed CIS subjects without lesions have PK binding similar to the 
HCs and CIS with lesions have PK binding values similar to the relapsing patients. Therefore 
the presence of WM lesions could represent a priming for microglia activation which can be 
detectable throughout the WM, in my results independently of the site of the lesion. Subjects 
in the progressive phase of the disease have a further, higher level of PK binding. Increasing 
the number and state of activation of microglia (Breij et al., 2008), paralleling an increased 
damage of axon and myelin (Magliozzi et al., 2010), the cerebral environment reaches a 
threshold beyond which its homeostasis brakes down and an overwhelming and relentless 
global tissue damage takes place (Gao et al., 2003; Huh et al., 2003; McGeer et al., 2003). 
This condition is typically the pathological correlate reported in subjects affected by 
progressive MS (Kutzelnigg et al., 2005). Literature regarding the role of activated microglia 
in NAWM is not consistent. Despite the fact that activated microglia in NAWM can be 
deemed as alerted but immunosuppressed (Melief et al., 2013) and can mimic the protective 
role of the preconditioning occurring during hypoxic injury (Graumann et al., 2003a), other 
evidence, including that provided in this study, suggests a detrimental role for activated 
microglia, which increases with the course of the disease (Aboul-Enein et al., 2010; Howell 
et al., 2010; Kutzelnigg et al., 2005; Tourbah et al., 1999; Wattjes et al., 2008). 
The results of my study, supporting a detrimental role for activated microglia in NAWM, are 
represented by the correlation between PK binding and disability, both in CIS subjects with 
WM lesions and in all the patients. Fig. 5.9 shows how these two variables parallel across the 
MS courses. Furthermore, the predictive role of NAWM PK binding for disease progression 
in SPMS subjects points out that the higher activation levels of microglia are constantly 
associated with worsening of patients disability until the late stages. According to this 
interpretation, several studies were performed inhibiting the microglia activation, in order to 
evaluate its specific role in EAE and MS. Heppner and coll. used transgenic CD11b-HSVTK 
mice to explore the microglia paralysis through administration of ganciclovir (Heppner et al., 
102 
 
2005). In brain slice culture from CD11b-HSVTK mice, ganciclovir was able to abolish the 
microglia secretion of nitrite, and proinflammatory cytokines and chemokines. In vivo, the 
development of EAE was repressed by administration of ganciclovir. In the cited study in 
which Howell showed an association of microglial activation with nodal and paranodal axo-
glial disruption, starting at the preclinical stage and still present during chronic EAE, the 
inhibition of microglia by administration of minocycline was able to resolve the 
inflammation, reversing and preserving the axo-glial integrity (Howell et al., 2010). In MOG-
induced EAE a combined therapy with minocycline and human bone marrow mesenchymal 
stem cells showed the combination to be more effective than each of the treatment alone in 
reducing the disability scores (Hou et al., 2013). 
The ample literature supporting a detrimental role for microglia activation both for the onset 
and the progression of MS together with the possibility of inhibiting microglia activation by 
administration of minocycline supported the launch of clinical trials on MS patients. One 
phase 2 study using minocycline as an add-on to GA in RRMS patients showed the subjects 
with combined therapy to have a reduction of T1 enhancing lesions by 63%, of new or 
enlarging T2 lesions by 65% and a lower, non-significant, risk of relapses (Metz et al., 2009). 
A second phase 2 trial investigating the effects of minocycline as add-on to IFNβ1a didnt 
show any significant difference between the groups, the study was disrupted by a high rate of 
patient withdrawal (data unpublished, ClinicalTrials.gov Identifier: NCT01134627). Finally, 
a phase 3 trial on CIS subjects will be completed in June 2015. This is a randomised double 
blind study with two arms - minocycline vs placebo - with the primary outcome being 
reduction in the conversion to McDonald MS (ClinicalTrials.gov Identifier: NCT00666887). 
However the microglia activation is likely needed to be modulated, rather than inhibited. 
Bhasin and coll. used the macrophage/microglia inhibitory factor and the stimulator tuftsin to 
modulate the microglia activation and its timing during MOG-induced EAE. In the same 
study, a further modulation consisted in the creation of tissue plasminogen activator (tPA)-
deficient mice, a condition in which stimulated microglia assume a milder activation state. 
The results showed that the inhibition and stimulation of microglia activation can be either 
beneficial or detrimental, depending both on the timing of their administration and on the 
level of this activation, according to the presence or not of the tPA gene. These different 
conditions were also shown to affect the Th1-Th2 balance (Bhasin et al., 2007). The presence 
of all these variables interfering with the activation state of microglia makes the context 
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extremely complex and the identification of a single and specific role for microglia 
activation, and their possible therapeutic modulation, in EAE/MS difficult to achieve yet. 
Uneven microglia activation in GM regions across MS courses 
The results of the GM study in my population show the GM being unevenly affected from the 
early stages of the disease to the latest progressive phases. In CIS subjects the CS have higher 
values of PK binding than HC and patients with lesions or who developed MS at 2 years even 
higher. There was no evidence of increased signal in other GM regions. The uneven 
distribution of the PK binding was found also in MS subjects. The ROI effect reported in 
GLM analysis highlighted specific regions such as the brainstem, with the PK binding 
correlating with disability in SP patients, or CS and cortical GM, where a higher PK binding 
was predictive of worse prognosis at two years, again only in SPMS. 
In a disease like MS, where several pathological changes occur at different stages and involve 
all the resident CNS population as well as the infiltrating immune cells from peripheral 
blood, it is difficult to discern clearly all the steps that lead to the final pathway of 
neurodegeneration associated with variable degrees of inflammation. GM changes can be 
found even at the RIS stages, when reduced NAA/Cr values at MRS were present in 61% of 
RIS compared with HC (Stromillo et al., 2013). Significant GM atrophy is reported from the 
RIS stage (Rojas et al., 2015) and thalamic atrophy is known to be present in CIS and early 
MS (Calabrese et al., 2011; Cifelli et al., 2002; Langkammer et al., 2013). In MS, atrophy is thought 
to increase by about 0.7-1%/year (Miller et al., 2002). The GM loss, measured by monthly 
MRI, was significant in only 9 months of FU in RR subjects (Valsasina et al., 2005), 
implying a continuous and rapidly progressive atrophy, which is known to be associated with 
neurological and cognitive disability (Benedict et al., 2006; Sanfilipo et al., 2005). 
Furthermore, GM pathology is reported to be uneven between specific regions (Bendfeldt et 
al., 2009), such as thalamus, hypothalamus, putamen and caudate (Henry et al., 2008), and to 
evolve according to the disease stages (Ceccarelli et al., 2008). 
However in MS, the atrophy due to neuronal loss and demyelination is associated with other 
relevant and specific pathological features: inflammation, oxidative stress with DNA damage 
and regenerative process in neurons and oligodendrocytes (Fischer et al., 2013). Neuronal 
death in MS can be attributed to many mechanisms, anterograde/retrograde degeneration 
from WM changes (Audoin et al., 2006; Dziedzic et al., 2010; Henry et al., 2009; Varga et 
al., 2009), direct adaptive immunity attack (Bartos et al., 2007; Mathey et al., 2007; Ousman 
et al., 2007; Silber et al., 2002), innate immunity over-activation with oxidative toxicity 
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(Fischer et al., 2012; Gray et al., 2008a), mitochondria-derived energy failure or even age-
dependent iron and copper accumulation (Bagnato et al., 2011; Mehta et al., 2013). However, 
neuronal death in MS, whether as a cause or a consequence, is consistently associated with 
activated microglia (Dutta and Trapp, 2007; Ferguson et al., 1997; Fischer et al., 2013; Gray 
et al., 2008b; Henderson et al., 2009; Howell et al., 2011; Kooi et al., 2009, 2012; 
Kreutzberg, 1996; Magliozzi et al., 2007; Peterson et al., 2001; Polazzi and Contestabile, 
2002; Prineas et al., 2001; Reynolds et al., 2011; Stys et al., 2012; Vercellino et al., 2007). It 
is indeed known that the final pathways of all the pathogenic mechanisms described  (Cunnea 
et al., 2011; Fischer et al., 2013; Graumann et al., 2003b; van Horssen et al., 2006, 2008; 
Kornek et al., 2001; McMahon et al., 2012; Mycko et al., 2012; Stahnke et al., 2007; Stys, 
2005; Vergo et al., 2011; Veto et al., 2010; de Vries et al., 2008; Waxman, 2008; Werner et 
al., 2001) are characterised by the association of neurodegeneration with microglia activation 
(Ferguson et al., 1997; Fischer et al., 2013; Kutzelnigg et al., 2005; Prineas et al., 2001). 
My study on GM showed that at the CIS stages some GM structures have detectable and 
significantly higher microglia activation than HC, which increases with the presence of WM 
lesions. Considering the already cited thalamic atrophy and neurodegeneration and the 
association of neurodegeneration with microglia activation, my PK-PET results on CIS CS 
can be considered consistent with the literature. The similar uneven distribution of the GM 
changes reported in my results is comparable with neuropathology and MRI studies. Despite 
this, the analysis of cortical GM resulted without any indication of regional (or global) 
microglia activation higher than HC. At the very early stages of MS, the primary contribution 
of activated microglia to the tissue damage should be mostly related to its function as APC. 
While the results reported in the NAWM study would be consistent (not only) with the APC 
role, the absence of detectable higher microglia activation in cortical GM would either make 
doubtful this role for microglia in cortical GM pathology or suggest that the differences in 
those regions are not sufficiently marked to be detected by the PK-PET methodology used. 
My findings in CS, would therefore either represent the association of microglia activation 
with neurodegeneration, even at the CIS stage, or suggest the higher sensibility of the PK-
PET to those ROIs. This could be related to the difficulty in quantifying microglia activation 
in a very thin region, such as atrophic cortex, and to the relatively paucity of microglial cells 
compared with the WM - Peterson reports a 6 fold higher CD68 positive cells in WM 
compared with GM lesions (Peterson et al., 2001). In my study this is further limited by the 
impossibility to distinguish between lesional and NAGM. 
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In MS, there was a consistent association between higher PK binding and worse outcome in 
progressive patients. This data further supports the role of activated microglia in contributing 
to the neurodegeneration in progressive MS. At this stage, when the microglia activation in 
rapidly progressing patients is at very high levels, the PK-PET methodology was shown to be 
sufficiently sensitive, reporting significant differences. One possible speculation about the 
pathological association with the cortical GM results is probably that the relevant variables 
are the amount of the neuronal damage and microglia activation, together with their extension 
throughout the cortex. When neurodegeneration and microglia activation is extremely diffuse 
and high, a threshold is reached where all the compensatory mechanisms, affecting each 
other, can fail abruptly. In my two SP subgroups this is what we may be seeing, one 
population with better prognosis remaining below, the other with worse prognosis above this 
threshold. The hypothesis of such a threshold, to be interpreted as the level of tolerable 
burden of counterbalancing capacity, is supported by a wide literature, reviewed by Mahad, 
Trapp and Lassmann (Mahad et al., 2015). This could also explain the high variability seen in 
the PK binding of SPMS patients, particularly evident in Fig. 6.6, and even in NAWM, Fig 
5.10, where the progressive group with high PKBPND could be accounted for by Kutzelnigg 
and coll. in their description of the very high and widespread microglia activation in NAWM 
associated with neurodegeneration (Kutzelnigg et al., 2005). 
 
Increasing clinical relevance of microglial activation in MS black holes according 
to the disease evolution 
In this study, the BH displayed a high degree of heterogeneity in the PK binding. The levels 
of microglia activation correlated with disability and prognosis only in progressive patients, 
whereas in relapsing MS subjects the PK binding was not associated with disability. In this 
subgroup of patients the smaller the lesions were the higher the PK binding. However the 
PKBPND in RRMS was not higher in patients with worse prognosis. 
In my MS population, PK-PET detectable microglial activation was present in over 75% of 
the BH identified, suggesting a possible pathological/clinical role for these lesions. Therefore 
T1-hypointense lesions in MS could represent not just holes, characterised by axonal loss 
and demyelination, but display an inflammatory activity that in this case was shown to have 
clinical relevance. In progressive patients the volume of BHPK
+
 and BHPK
0
 were equally 
distributed, while in relapsing subjects the BHPK
+
 had higher volume than the BHPK
0
 and 
the microglia activation
 
was less than in progressive patients. This is important considering 
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some studies on the pathological correlate of BH (Brück et al., 1997, van Walderveen et al., 
1998) in which, as my results indicate, T1-hypointense lesions seem to have different clinical 
and pathological characteristics in relapsing and progressive MS patients. 
The clinical importance of this study in progressive MS patients consists in the correlation 
between PKBPND in the BH and their disability, and the relevance that microglia activation 
has in their prognosis. These results add information to the previous inconsistent literature 
regarding the role of MS BH in patients disability (Truyen et al., 1996, Giugni et al., 1997, 
O'Riordan et al., 1998, Paolillo et al., 1999, van Walderveen et al., 1999a, Simon et al., 2000, 
Masek et al., 2008). This link between PK binding in BH and disability in SPMS, supports 
the association between high microglia activation and neurodegeneration, the presumed main 
pathological correlate of permanent disability in MS (Reynolds et al., 2011). 
In relapsing MS patients the PK binding displayed in BH doesnt support the same clinical 
and possibly pathological role for microglial activation. Because the lack of correlation in this 
group between PK binding and disability, it is likely that in BH of relapsing patients the 
microglia activation is less associated with neurodegeneration. This discrepancy might 
represent a condition in which higher levels of inflammation are not associated with neuronal 
sufferance. The fact that RRMS patients were recruited during the clinical remission phase 
doesnt imply necessarily lower levels of microglia activation. However, innate immune 
activity, as reported in the introduction, is not necessarily associated with tissue damage and 
clinical worsening, as seems to be the case with my relapsing patients. Moreover, the three 
highest levels of PK binding in BH of relapsing patients were found in subjects with low 
EDSS scores (average respectively PKBPND 15.134 and EDSS 4.2, median 4.0) compared 
with the rest of relapsing patients (average respectively PKBPND 5.390 and EDSS 5.7, median 
6.0). It is worth mentioning that the total PKBPND values in those 3 relapsing patients would 
place them into the group of progressive patients with worse prognosis (group A). Contrary to 
the progressive, the PKBPND in relapsing patients was higher, even if not significant, in the 
group with better prognosis and inversely correlated with the BH volume load. These results 
may suggest that, rather than the level and extension of microglia activation, a qualitative 
aspect may be more relevant, such as the microglia phenotype, which investigation is 
unfortunately beyond the possibility of the methodology here used. The different clinical 
characteristics associated with high PKBPND in relapsing and progressive groups could 
therefore imply that microglial activation has different roles depending on the stage of 
disease. One possible interpretation of the results of this part of the PK-PET study is that, at 
least in BH, microglial activation indicates different underlying pathological processes in 
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relapsing and progressive patients. This is also supported by epidemiological studies 
(Kremenchutzky et al., 2006), in which the progressive phase seems to be independent of 
relapses; by radiological studies (Rocca et al., 2003), where the focal lesions are not 
considered sufficient to explain the progressive neurodegeneration and disability 
accumulation. In neuropathology studies (Trapp et al., 1999), the disability occurring during 
relapses is mostly supported by inflammatory infiltrated from the peripheral immune cells 
and demyelination, whereas the remission is associated with resolution of the inflammation 
and remyelination. On the contrary, the compartmentalisation of the immune response is 
reported as characteristic of the progressive phase and consistently associated with 
neurodegeneration. Finally, the DMTs available for MS act mostly on the adaptive immune 
system and their efficacy results in reducing the relapse rate. However, their ability to affect 
the disability progression, and the associated relentless neurodegeneration, has been shown to 
be limited. 
My opinion is that in progressive subjects the high PKBPND found in this BH study could 
arise from compartmentalised inflammation and be associated with neurodegeneration. As 
suggested by the results, the microglial activation seen here in relapsing MS is driven by 
inflammatory demyelination not associated with excessive axonal sufferance. These findings 
in relapsing MS may represent further evidence that microglia activation itself is neither 
necessarily associated with tissue damage nor entails the detrimental role of increasing 
neurodegeneration causing permanent disability. 
 
Limitations 
Although my study provides new and useful information on the in vivo imaging of activated 
microglia in new regions of interest, it has a number of limitations. First of all, despite the 
number of subjects enrolled is powered to achieve significant results for a PET study, the 
subdivision of the various populations in subgroups reduces this power. This is true for the 
CIS patients, when they have been divided in subjects with or without lesions, with MS 
diagnosis at FU or not. This also occurred in MS patients, divided into progressive and 
relapsing and further divided according to their prognosis. Moreover, with regard to the MS 
subjects, there is  also a wide range of disease duration in the relapsing group, 1.019.0 years 
(mean 12.5 years); furthermore, relapsing patients had a rather severe disability (mean EDSS 
5.3, median 5) allowing concerns about a possible underlying progression, which could have 
affected the results in this population. 
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The MRI methodology in this thesis was used only for colocalization with PK-PET scans. 
MRI scans were therefore performed only at cerebral level, not including the spinal cord. 
Hence, despite it is likely that possible spinal cord lesions could have affected the disability 
scores in my population, it was not the aim of this study to find MRI correlates to subjects 
disability. Moreover, all the CIS subjects with a spinal cord syndrome also presented cerebral 
WM lesions, excluding the possibility that they were wrongly considered in the group of 
CIS without lesions and therefore the possibility of incorrect interpretation of the results. 
With regard to the specific studies, I have already mentioned the possible impaired power of 
the methodology regarding the ability in detecting activated microglia in cortical GM, 
especially in the later stages of the disease. This is due to lower microglia activation in GM 
compared with WM, to the presence of high levels of cortical atrophy in progressive patients 
and to the limited spatial resolution of the PET. With regard to the BH, the lower limit for 
volume (3mm
3
), however consistent with the criteria reported in literature, might be 
susceptible to partial volume effects; despite in my study the smaller BH had higher PKBPND 
values, partial volume effect may have affected the results regarding the BH volumetric 
distribution and their correlation with PK binding. 
CIS subjects were aged compared to the MS age at onset. My CIS population mean age was 
38.5 years, which is higher than those reported by Fisniku (32 years) and Chard (33.9 years) 
and the age at onset of MS subjects in my population was 23.9 years. However, considering 
the low number of subjects in my thesis compared to studies performed on larger population, 
this is not an unusual occurrence and I believe that it unlikely affected the results and 
interpretation of my work. With regard to the HC in comparison with the CIS population, 
despite the latter mean age was lower, it was shown to not affect the PKBP (Kumar et al., 
2012). Furthermore, when I used the age as a covariate, its effect resulted not significant. 
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CHAPTER 9: Conclusions 
In conclusion, in this study microglia activation has been explored in vivo using PK-PET 
imaging in subjects with different stages of MS, including a wide range of disability (from 0 
to 9.5 of EDSS) and courses (HC, CIS, RR and progressive subjects). I examined the regions 
(NAWM, GM and BH) that are more relevant for understanding the pathological changes in 
MS and the role of activated microglia. With regard to the NAWM, I found an increasing 
microglia activation, from the earlier stages (CIS) to the later ones (progressive patients). 
This increase can also have prognostic values, especially for CIS and progressive subjects. 
Furthermore, the results on NAWM parallel the pathological findings reported in literature. 
The results on the GM showed the importance of the CS for CIS and a possible prognostic 
value for the cortex in progressive patients. However, the uneven distribution of PK binding 
in GM and the limitations already reported make the study of GM with this methodology 
more difficult to be interpreted and probably highlight the need for larger population. With 
regard to the BH, they also showed a possible prognostic value for progressive patients. 
Finally, in this study I report for the first time the in vivo visualization of microglia activation 
before the symptoms of an MS relapse onset and in absence of MRI detectable BBB 
disruption. 
This study confirmed the importance of activated microglia during the early stages, when the 
disease develops, entailing the innate immunity property of this cell population. In later 
stages their prognostic value is consistent with the known association between 
neurodegeneration and a detrimental microglia over-activation. Considering these 
observation, PK-PET could be an important tool in trials evaluating the effects of new drugs 
either for CIS early treatment and disability progression of MS. 
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APPENDIX: Expression of TSPO at cellular level in human post-mortem 
brain tissue 
Background 
The TSPO has been considered for long time as a molecule expression of activated microglia 
and therefore used as target for PET tracer aiming the study of activated microglia in CNS. 
However, the literature is not consistent about the possible contribution of astrocytes to the 
overall TSPO expression in brain tissue (Table A1). Furthermore, since the TSPO is 
potentially expressed, even if at very low levels, by other cell populations I considered the 
possibility to explore the TSPO expression in HC and MS PM brains, by using double 
immunofluorescence. 
Aim 
This is an exploratory study to evaluate the contribution of TSPO expression by cell 
populations other than activated microglia, in the PM CNS of MS and HC subjects. 
Methods 
The population of this exploratory study consists of three HC and one MS PM brains 
pertaining to the MS Tissue Bank (MSTB) at Imperial College London. Tissue from HC was 
provided by the MSTB in paraffin-embedded and formalin-fixed blocks. The MS brain was 
first MRI scanned and formalin-fixed (within 23 hours from death), then a second MRI scan 
was performed and the brain cut up and embedded in paraffin. The following ROIs were 
defined on the first MRI scan: WM lesion, NAWM, BH, cortical lesion (CL), normal 
appearing cortex. The second MRI was used for coregistration allowing the localisation of 
ROIs after the shape and size changes of the brain due to fixation. The MRI scans were 
performed immersing the brain in a proton-free liquid, Fomblin®. 
Selected ROIs were then studied with double immunofluorescence, TSPO and antibodies 
specific for different cell populations, Iba-1 for microglia, MRP14 for activated microglia, 
GFAP for astrocytes, NeuN and SMI32 for neurons, CD3 and CD20 for lymphocytes. In 
order to reduce the occurrence of autofluorescence, slides were treated with Sudan BlackB. 
Analyses were performed both evaluating the colocalising pixels (automatically) and 
counting the colocalising cells (operator-dependent). For each Ab, measurements were 
carried out on fields at 20X of magnitude on at least 10 fields in 3 consecutive slices for each 
ROI. Vessels expressing TSPO were evaluated on the GFAP-stained slides images, again 
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both measuring pixels and counting cell. In order to automatically measure the colocalising 
pixels, I draw a macro running on ImageJ software. 
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Author Reference Method Tissue Finding Pathology 
Bourdiol et 
al. 
Brain Res 
1991 
[
3
H]PK14105 
or 
[
3
H]PK11195 
rat cerebral 
cortex and 
striatum 
After injection of IL-1, TNF-a, LPS, the TSPO expression increased through the 
following sequence: 1) microglial activation, 2) release of IL-1 and/or TNF-a, 3) 
astroglial reaction. [microglia initially, then astrocytes]  
Inflammation 
Stephenson 
et al. 
J Neurosci 
1995 
[
3
H]PK11195 transient global 
forebrain 
ischemia 
Looking at the regional distribution, authors report that microglia rather than 
astrocytes bind [
3
H]PK 11195 
 
Ischaemia 
Vowinckel 
et al. 
J Neurosci Res 
1997 
[
3
H]PK11195 
/ IHC 
EAE Correlation at sites of inflammatory lesions between [
3
H]-PK11195 binding and 
immunoreactivity for the activated microglial/macrophage marker Mac-1/CD11b 
MS and MS 
models 
[
3
H]PK11195 
/ IHC 
MS brain tissue [
3
H]-PK11195 binding correlated with sites of immunoreactivity for the microglial/ 
macrophage marker CD68, at the edges of chronic active plaques 
MS and MS 
models 
Banati et al. J Neurocytol 
1997 
[
3
H]PK11195 rat axonotomy Colocalization with activated microglia. The full transformation of microglia into 
parenchymal phagocytes is not necessary to reach maximal levels of PK binding. 
PK11195, therefore, is able to detect microglial activation in areas of subtle brain 
pathology, where neither a disturbance of the BBB function nor the presence of 
macrophages and inflammatory cells indicate an on-going disease process 
Neural injury 
Conway et 
al. 
Neuroscience 
1998 
[
3
H]PK11195 
In situ 
hybridization 
for GFAP 
transient global 
forebrain 
ischaemia in rat 
Spatial and temporal changes of GFAP and [
3
H]PK11195. 
Conclusion: differences in temporal expression of GFAP messenger RNA and 
[
3
H]PK11195 binding support the proposed localization of PBR on activated 
microglia, as distinct from reactive astrocytes 
Ischaemia 
Banati et al. Brain 2000 [
3
H]PK11195 EAE/MS Brain 
tissue 
PBR expressed in focal inflammatory sites by invading blood-born cells 
(macrophages) 
MS and MS 
models 
Kuhlmann 
and 
Guilarte 
J Neurochem 
2000 
[
3
H]PK11195 
/ IF 
rat with 
trimethyltin 
(neurotoxic) 
The onset of the astroglia response is delayed, but more persistent, compared with 
microgliosis. Both astrocytes and microglia are capable of expressing high levels of 
PBR after injury 
Neural injury 
Le 
Goascogne 
et al. 
Glia 2000 IHC/IF jimpy and 
shiverer mice 
PBR was expressed in many reactive astrocytes of mice brains 
 
Demyelinaiton 
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Author Reference Method Tissue Finding Pathology 
Sauvageau 
et al. 
Metab brain 
dis 2002 
[
3
H]PK11195 human dissected 
hippocampi 
Increased in hippocampal sclerosis, associated to gliosis 
 
Neural injury 
Chen et al. Brain 2004 [
3
H]-(R)-PK11195 
and [
125
I]-(R)-
PK11195 
mice with 
cuprizone 
1. PBR levels were associated with the degree of demyelination and 
activation of glial cells assessed by GFAP IHC for astrocytes and CD11b 
(Mac-1) for microglia. PBR increase prior to demyelination. Striatum: 
correlation between microglial activation and increased PBR levels in 
demyelinating fibre tracts; deep cerebellar nuclei express both markers; in 
corpus callosum microglia is early expressed, then both microglia and 
astrocytes 
2. With regards to the colocalization (autoradiography + IHC) PBR 
colocalized with both microglia and astrocytes 
Demyelinaiton 
Chen and 
Guilarte 
J toxicol sci 
2006 
[
3
H]-(R)-PK11195 
 
mice with 
cuprizone 
Quantitative autoradiography of 
3
H-(R)-PK11195 binding to PBR in the 
corpus callosum showed increased levels at 3 weeks of demyelination and 
gradually decreased as a function of remyelination. PBR levels were 
associated with the degree of remyelination and activation of microglia and 
astrocytes. However, the temporal pattern suggests that the PBR signal 
during the late stages of remyelination was primarily associated with 
astrocytes 
 
Demyelinaiton 
Maeda et 
al. 
Brain Res 
2007 
Autoradiography 
with 
[
11
C]DAA1106 
IF 
rat with ethanol Increased expression of PBR in astrocytes was transiently observed in a 
manner parallel to the centripetal migration of these cells to the 
inflammatory lesion. Thereafter, astrocytic PBR was barely detectable. By 
contrast, intense PBR signals were persistently present in microglia 
localized to the injury epicenter up to 90 days, notwithstanding a gradual 
reduction in the number of ionized calcium binding adapter molecule-1-
positive amoeboid microglia between 7 and 90 days. 
Neural injury 
Rojas et al. J Cereb Blood 
Flow Metab 
2007 
[
3
H]PK11195 
[
11
C]-PK11195 
PCR 
IHC 
rats after transient 
focal cerebral 
ischemia 
Reactive astrocytes forming a rim surrounding infarction at day 7 also 
showed some PBR immunostaining. These results show cellular 
heterogeneity in the level of PBR expression, supporting that PBR is not a 
simple marker of inflammation, and that the extent of [
11
C]PK11195 
binding depends on intrinsic features of the inflammatory cells 
Ischaemia 
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Author Reference Method Tissue Finding Pathology 
Ji et al. J Neurosci 
2008 
Autoradiography 
with DAA1106 
IF 
AD and non-AD 
mice model of 
neurodegeneration 
1. AD-like Aβ deposition is concurrent with astrocyte-dominant PBR 
expression, in contrast with non-astroglial PBR upregulation in 
accumulations of AD-like phosphorylated tau 
2. Non-AD neuropathologies: (a) PBR-deficient astrogliosis uncoupled 
with microgliosis or coupled with microgliosis expressing PBR 
associated with irreversible neuronal insults; (b) PBR positive 
astrogliosis coupled with microgliosis associated with minimal or 
reversible neuronal toxicity 
3. Non-toxic microglia drives astroglial PBR expression 
Conclusions: PBR expressions in astrocytes and microglia reflect 
respectively beneficial and deleterious glial reactions 
Neurodegeneration 
Cosenza-
Nashat et al. 
Neuropathol 
Appl 
Neurobiol 
2009 
IHC PM human brains 
from controls, HIV 
encephalitis, AD, 
MS and stroke 
Normal brain: TSPO+ cells were identifiable as microglia or astrocytes. 
The vascular wall stains were also highly punctate. Intravascular 
monocytes were detected. 
MS: TSPO stain was present in scattered fibrillary astrocytes. Adjacent 
NAWM was devoid of staining. Acute MS lesion contained a number of 
TSPO+ phagocytic macrophages throughout the plaque. Adjacent brain 
showed neuronal staining as well as focal microglial staining. 
Conclusions: macrophages and microglia are the predominant TSPO+ 
cells in acute MS; in chronic and silent MS lesions, reactive astrocytes 
can also express TSPO 
MS and MS models 
Venneti et al. J Neuropathol 
Exp Neurol 
2008 
[
3
H](R)- 
PK11195 
[
3
H]DAA1106 
PM human brain Combined immunostaining for astrocytes (GFAP) and activated 
microglia (CD68) with [
3
H]-(R)-PK11195 or [
3
H]DAA1106 
autoradiography. 
Binding values correlated with activated microglia, assessed in the same 
area in these same cases with both tracers 
MS and 
neurodegenerative 
Venneti et al. Neurobiol 
Aging 2009 
[
3
H](R)-
PK11195 
AD human brain 
APP/PS1 
transgenic mice 
[
3
H](R)-PK11195 binding was significantly higher in AD frontal cortex 
compared to controls and correlated mainly with activated microglia 
Neural injury 
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Table A1. Studies reporting the expression of the TSPO in CNS structures at cellular level, in 
controls and different pathological conditions. Aβ: Amyloid beta; AD: Alzheimers disease; BBB: 
blood-brain barrier; EAE: experimental autoimmune encephalomyelitis; GFAP: glial fibrillary acidic 
protein; IF: immunofluorescence; IHC: immunohistochemistry; IL: interleukin; LPS: lipopolysaccharide; 
MS: multiple sclerosis; PBR: peripheral benzodiazepine receptor; PM: post mortem; TNF: tumor necrosis 
factor; TSPO: translocator protein; 
 
Results 
The MS case, female, presented the disease onset at 32 years. At the time of death the subject 
was reported to have a SP course. Disability was mainly due to walking difficulty and impaired 
balance. The death was caused by aspiration pneumonia at the age of 68 years. The first control, 
male, died at the age of 64 years for myocardial infarction and his medical history was positive 
for TIAs. The second control, male, died at the age of 35 years for carcinoma of the tongue and 
was also affected by migraine and hypertension. The third control, female, died at the age of 67 
years for acute arrhythmia and her medical history was positive for myocardial infarction, 
hypertension and duodenal ulcer. 
From the MS brain, a total of 65 ROIs were sampled, 10 from WM lesions, 18 from BH, 15 from 
CL, 12 from NAWM and 10 from normal appearing cortex. From each control brain, 6 WM and 
6 GM ROIs were sampled, for a total of 36 ROIs within all the controls. 
The results of the cell counting (Fig. A1a) showed an overall expression of TSPO in HC subjects 
by the following cell population: 69.4% microglia (6.4% active), 7.7% astrocytes, 5.1% vessels, 
2.8% neurons and 0.06% lymphocytes. In the MS brain the cell counting showed an overall 
expression of TSPO by the following cell population: 25.4% microglia (18.2% active), 6.4% 
astrocytes, 24.4% vessels, 2.2% neurons and 10% lymphocytes. The results of the pixel 
measurements (Fig. A1b) showed an overall expression of TSPO in HC subjects by the 
following cell population: 76.6% microglia (6.4% active), 5.7% astrocytes, 5.1% vessels, 1% 
neurons and 0% lymphocytes. In the MS brain the pixel measurements showed an overall 
expression of TSPO by the following cell population: 30.3% microglia (48.6% active), 21.1% 
astrocytes, 13.8% vessels, 5.7% neurons and 17.8% lymphocytes. 
The cell counting and pixels measurements regarding the different ROIs studied in the MS case 
are reported respectively in Tab. A2 and A3. 
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Figure A1. Cerebral expression of TSPO at cellular level by MS and HC. On the Y axis the 
percentage of TSPO (in red) colocalization with other cell-specific antibodies (X axis). The controls are 
represented by green bars, while the MS by blue bars. In (A) the results regarding the cell counting; in (B) 
the results regarding the pizel measurements. 
 
CELLS - MS ALL NAWM WM lesions NA Cortex Cortical lesions BH 
Iba1 25.36 28.85 20.93 21.41 31.32 22.65 
MRP14 18.22 16.53 13.93 38.18 16.75 6.32 
GFAP 6.35 1.34 13.34 0.26 1.59 10.79 
Vascular 24.36 22.17 21.43 23.73 40.34 18.53 
NeuN/SMI32 2.20 0.00 0.00 3.59 7.30 0.00 
CD3/CD20 10.02 13.89 15.09 3.27 4.17 13.55 
Table A2. Cellular TSPO expression results. Percentage of TSPO colocalization at cellular level with 
Antibodies binding several different cell populations, according to the ROIs selected for the MS brain. 
MS: multiple sclerosis; NAWM: normal appearing white matter; NA: normal appearing; BH: black holes; 
Iba-1: microglia/macrophage; MRP14 active microglia/macrophage; GFAP: astrocytes; NeuN/SMI32: 
neurons; CD3/CD20 lymphocytes. 
 
PIXELS - MS ALL NAWM WM lesions NA Cortex Cortical lesions BH 
Iba1 30.30 22.06 30.49 32.66 34.10 30.07 
MRP14 48.63 44.88 42.32 60.27 54.21 32.57 
GFAP 21.06 18.22 32.00 6.00 5.45 33.13 
Vascular 13.80 15.37 11.29 13.04 18.07 11.75 
NeuN/SMI32 5.70 0.00 0.00 30.05 29.29 0.00 
CD3/CD20 17.84 20.83 22.31 16.47 13.47 15.26 
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Table A3. TSPO expression results at pixel measurements. Percentage of TSPO colocalization at pixel 
level with antibodies binding several different cell populations, according to the ROIs selected for the MS 
brain. MS: multiple sclerosis; NAWM: normal appearing white matter; NA: normal appearing; BH: black 
holes; Iba-1: microglia/macrophage; MRP14 active microglia/macrophage; GFAP: astrocytes; 
NeuN/SMI32: neurons; CD3/CD20 lymphocytes. 
 
Discussion 
In this exploratory study the expression of TSPO in brain tissue was investigated in order to 
determine the cellular source. Three controls and one MS PM brains were sampled and double 
immunofluorescence performed with TSPO against cellular-specific antibodies expressed in 
microglia, astrocytes, neurons or lymphocytes. 
The results show that the principal cell population expressing TSPO is represented by microglia. 
However, a smaller amount of TSPO can be found in astrocytes, neurons and lymphocytes. The 
TSPO expression by blood vessel was already reported and corrected in this thesis project 
(Tomasi et al., 2008). 
One interesting result regards the difference between normal and MS brain expression of TSPO. 
While in normal brains the source of TSPO is almost exclusive of microglial cells, in 
pathological condition, such as neuroinflammation due to MS, other cell population can present 
remarkable expression of TSPO. Hence, in the MS brain, up to 6% of TSPO can be expressed by 
astrocytes, 2% by neurons and 10% by lymphocytes. Moreover, MS brain showed a marked 
prevalence of activated microglia compared to controls, as well as higher TSPO expression by 
the blood vessels. 
Another interesting result concerns the TSPO expression in different normal/pathological region 
of MS brain. The most remarkable differences in the NAWM are represented by very low 
expression of TSPO in astrocytes and high expression in lymphocytes; in WM lesions and BH 
both the astrocytes and lymphocytes have higher amount of TSPO, compared to the average; in 
normal appearing cortex the very low expression of TSPO by astrocytes represents the most 
remarkable result, while in cortical lesions the endothelial cells resulted by far the cell population 
with higher TSPO expression. 
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Being this an exploratory study there is a list of limitations that particularly affect the possibility 
to provide definitive results and the accuracy of their interpretation. 
First of all, the number of brans studied is extremely limited, especially considering that only one 
brain was pertaining to an MS case, the others being controls. 
The reason for death and the health condition preceding the death can have significantly affected 
the expression of TSPO. Within these, the presence of systemic infection, ischaemic sufferance 
or possible presence of neoplastic cell, represent only the major examples. One finding in favour 
of those confounding factors is that both for the cell counting and the pixel measurements, the 
amount of TSPO was higher in controls than in MS cases. 
A further possible confounder is represented by the occurrence of autofluorence, which increases 
with the age of the brain and is highly present in the paraffin-embedded tissue. An example of 
how the autofluorescence could have interfered with the results is the high amount of neurons in 
the double fluorescence colocalization, especially for the automatic pixel measurement. 
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